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ABSTRACT 
 To combat the rise of foodborne disease outbreaks in fresh and ready-to-eat (RTE) 
meats and to reduce further bacterial drug resistance, researchers are looking to natural and 
chemical alternatives to antibiotics.  These alternatives include, but are not limited to, plant 
and herbal extracts, vaccines, and bacterial proteins.  One alternative, bacteriocins, are being 
used in livestock production, food manufacturing and processing, and retail packaging and 
sanitization.  Bacteriocins are proteinaceous compounds produced by and lethal to bacteria of 
species similar to the producing strain.  Various bacteriocins—including nisin, colicin, 
pediocin, cloacin, and lactic acid bacterial peptides—have been evaluated for use in food 
products or animal production as antibacterial strategies.  Colicins, specifically, are produced 
by certain strains of Escherichia coli and like species.  Bacteriocins within the colicin family 
have been shown to have several different killing mechanisms including pore-formation, 
nuclease activity against the DNA and RNA of target cells, as well as inhibition of protein 
synthesis.  Work presented in this dissertation involves the use of colicin E1, a pore-forming 
colicin, against E. coli O157:H7, as well as the first documented antimicrobial efficacy of 
colicin E1 against the gram-positive pathogen Listeria monocytogenes.  Colicin E1  
provided powerful reduction of E. coli O157:H7 as a beef carcass spray intervention.  Further 
testing with this bacteriocin demonstrated its unexpected inhibitory activity against the  
gram-positive pathogen Listeria monocytogenes.  The mechanism of action of colicin E1 
against L. monocytogenes was investigated using flow cytometry, spectrophotmetric leakage 
assays, and both light and transmission electron microscopies.  Colicin E1 had direct affinity 
to several L. monocytogenes proteins.  These proteins were discovered using affinity 
chromatography and identified using MALDI-TOF.  These colicin E1-binding proteins 
vii 
 
included DNA polymerase III, LepA, and a cell wall anchor family protein.  At this point, 
there is no literature stating any colicin having interaction with these proteins, suggesting 
Colicin E1 exerts its antimicrobial activity against L. monocytogenes in an independent and 
novel fashion. 
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CHAPTER 1.  GENERAL INTRODUCTION 
Introduction 
 Acute gastroenteritis affects 250 to 350 million people in the United States annually, 
and an estimated 22 to 30% of these cases are attributed to foodborne disease (97).  Although 
the causes of many foodborne outbreaks reported to the CDC are unknown, the leading 
known causes are viral and bacterial.  A broad spectrum of microbial pathogens can 
contaminate human food and water supplies and cause illness after they or their toxins are 
consumed.   
 Initial interest in the use of antibiotics to combat the rise of foodborne diseases has 
been tempered by the recognition that antibiotic overuse has led to the development of 
bacterial resistance to these compounds (76, 144).  
 In an effort to reduce further bacterial drug resistance, researchers are looking to 
natural and chemical alternatives to antibiotics—termed antimicrobials—in livestock 
production, food manufacturing and processing, and in retail packaging systems (7, 143).  A 
variety of treatments for prevention of food spoilage and pathogenic bacterial contamination 
have been investigated, including nonmicrobial enzymes or peptides such as lysozyme, 
lactoferrin and magainins; plant-derived products such as herbs and spices or essential oils 
derived from these; and microbial metabolites including hydrogen peroxide, organic acids, 
and bacteriocins (143).  Bacteriocins are proteinaceous compounds produced by, and lethal 
to, bacteria of species similar to the producing strain.  Such bacteriocins as nisin, colicin, 
pediocin, cloacin, and lactic acid bacterial peptides have been evaluated for use in food 
products or animal production as antibacterial strategies (123).  Colicins, specifically, are 
produced by certain strains of Escherichia coli and like species.  Colicins have several 
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different killing mechanisms within their protein family including pore-formation, nuclease 
activity against the DNA and RNA of target cells, and inhibition of protein synthesis (27).  
Several colicins have shown to be effective against gram-negative pathogens, such as E. coli 
O157:H7 and Salmonella enterica Ser. Typhimurium (24, 39).  Work presented within this 
dissertation provides insight into a specific colicin, colicin E1, and its ability to kill E. coli 
O157:H7, as well as the gram-positive pathogen Listeria monocytogenes.  Bacteriocins such 
as colicins have previously been thought to have an extremely narrow range of killing ability 
and seldom are active against differing groups of bacteria (27).  Therefore, the mechanism of 
action for colicin against gram-positive bacteria such as Listeria is of great interest.  
 This dissertation reports the use of bacteriocin antimicrobials in animal production 
and meat and poultry products for the control of foodborne pathogens.  Specifically, the use 
of colicins and colicin E1 in different livestock, meat, and poultry processing applications 
were evaluated.   
Dissertation Organization 
 This dissertation was compiled following an alternative journal paper format.  
Contents include general introduction and review of the literature, followed by three separate 
chapters in which journal articles already published in or submitted to peer-reviewed 
scientific journals will be presented.  A brief conclusion is included at the end of the 
dissertation.   
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Literature Review 
Part 1.  An Introduction to E. coli Species and Listeria monocytogenes 
Escherichia Coli     
 Escherichia coli (E. coli) are gram-negative bacteria belonging to the family 
Enterobacteriaceae.  Bacteria belonging to this family are commonly referred to as 
“enterics” as they are inhabitants of human and animal gastrointestinal tracts.  Approximately 
0.1% of the total bacteria within an adult's intestinal tract are represented by E. coli (141).  
Although limited in overall number, E. coli are the predominant facultative anaerobe bacteria 
found in this environment.  The colonization of the large intestine by nonpathogenic E. coli, 
as well by as other types of enterobacteria, promotes intestinal health.  These bacteria 
synthesize compounds such as K and B-complex vitamins which are then absorbed by the 
body.  E. coli strains are mostly benign and rarely cause adverse effects.  Some E. coli 
strains, however, have acquired the ability to cause infections ranging from intestinal 
disruption to meningitis and sepsis.   
 Given the mortality associated with the disease-causing strains, the primary research 
focus was placed on distinguishing benign and pathogenic strains of E. coli.  There are over 
700 different serovars of known E. coli that differ by distinguishing somatic (O) antigens  
and the flagellar (H) antigens.  The O antigen is a lipopolysaccharide which identifies the 
serogroup of the strain, and the H antigen identifies its serotype.  These antigenic 
determinants function as epidemiological detection tools.  There are seven total groupings of 
pathogenic E. coli, called virotypes, including opportunistic E. coli, enteropathogenic E. coli 
(EPEC), enteroaggregative E. coli (EAEC), enterohaemorrhagic or shiga-toxin-producing  
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E. coli (EHEC/STEC), enteroinvasive E. coli (EIEC), diffusely adhering E. coli (DAEC), and 
enterotoxigenic E. coli (ETEC) (110).  The virotyping scheme used groups of E. coli strains 
based on virulence characteristics such as toxin production and invasiveness; each virotype 
has a different pathogenesis and comprises a different set of O:H serotypes.  The seven basic 
virotypes of pathogenic E. coli are described in further detail below. 
 Opportunistic E. coli.  Opportunistic Escherichia coli are nonpathogenic unless an 
environmental change within the gastrointestinal tract promotes overpopulation and growth 
of the bacteria.  Opportunistic behavior is typical in postsurgical wounds, on surgical 
implants (49), urinary tract infections, and peritonitis (12).   
 Enteropathogenic E. coli.  EPEC strains are classically associated with diarrhea in 
young children (110).  The most prevalent association of EPEC is with infants and young 
children in developing countries with high mortality rates of between 10 and 40% (35).  
Outbreaks of EPEC occur where children are in close contact such as in nurseries and 
daycare centers (154).  The first stage in EPEC pathogenesis involves the initial adherence of 
bacteria to epithelial cells.  This adherence is initiated in part by the bundle-forming-pilus 
proteins (BFP) secreted by EPEC.  EPEC strains typically infect intestines via “attaching-
and-effacing” (110).  Using this virulence strategy, EPEC induces substantial cytoskeletal 
alterations in the intestine, which disrupts the brush border cytoskeleton and leads to a 
proliferation of filamentous actin beneath adherent bacteria.  Effacement of the intestinal 
microvilli and intimate adherence between the bacterium and the epithelial cell membrane 
are also associated with EPEC infection (142).  Other virulence factors include EPEC’s use 
of a type III secretion apparatus.  This system is utilized by many enteric pathogens, and it 
acts as a macromolecular syringe to inject effector proteins directly into host cells.  The 
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effector proteins secreted are associated with the previously mentioned attachment and 
effacing mechanisms on epithelial cells (35).  The underlying intereactions of other processes 
with EPEC-related diarrhea resulting from EPEC infection is still under investigation; 
however, the dramatic loss of microvilli and the subsequent malabsorption due to brush 
border enzyme deficiency certainly drive this resulting effect.  
 Enteroaggregative E. coli.  Nataro and Kaper (110) were the first to describe EAEC 
in culture.  Using a common adhesion assay using HEp-2 cells, these researchers found that 
certain strains of E. coli exhibit characterized by a “stacked-brick” formation of bacterial 
cells attached to the HEp-2 cells.  This “aggregative” characteristic sets these strains apart 
from other virotypes of E. coli.  Typical illness due to EAEC infection is characterized by 
watery, mucoid, and secretory diarrhea with low-grade fever and little to no vomiting (13).  
The basic strategy of EAEC is to comprise colonization of the intestinal mucosa—
predominantly that of the colon—followed by secretion of enterotoxins and cytotoxins (110).  
EAEC strains characteristically enhance mucus secretion from the mucosa, with trapping of 
the bacteria in a bacterium-mucus biofilm (110).  This heavy biofilm is related to the EAEC’s 
ability to cause persistent colonization and diarrhea (73).  In addition to forming a mucous 
biofilm, many EAEC strains induce cytotoxic effects on the intestinal mucosa including 
microvilli shortening and necrosis.  Virulence factors associated with EAEC are a heat-stable 
toxin and several aggregative adherence fimbriae (128, 109).   
 Enterohemorrhagic E. coli.  EHEC can be found in the fecal flora of a wide variety 
of animals, but the most important animal specie in terms of human infection is cattle.  
Colonization in beef cattle leads to an abnormally high prevalence of EHEC in cattle 
transport and lairage, which can contaminate carcasses during slaughter and subsequently 
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onto retail product.  The pathogenesis involves establishment of EHEC in the gastrointestinal 
tract where it has to compete for space and nutrients with other microorganisms of the 
normal intestinal microflora.  The most important virulence characteristic of the organism, 
once established, is its ability to produce one or more phage encoded verocytotoxins or Shiga 
toxins.  It is generally believed that after intestinal infection with EHEC, Stxs cross the 
intestinal barrier and bind to endothelial cells.  At this point they presumably injure the host 
cell by inhibition of protein synthesis, stimulation of prothrombotic messages, or induction of 
apoptosis.  The actions of these toxins on intestinal tissues cause the development of bloody 
diarrhea.  Hemolytic Uremic Syndrome (HUS) is the microvascular disease resulting from 
toxin entrance in the blood stream.  Once circulating, the toxins can bind to receptors on 
endothelial cells associated with the kidneys and brain (86).  This association leads to renal 
failure and hemolytic anemia.  
 The most important EHEC serotype implicated worldwide is O157:H7.  Escherichia 
coli serotype 0157:H7 is a known cause of hemorrhagic colitis and HUS.  Hemorrhagic 
colitis is acute disease caused by E. coli O157:H7 and is characterized by severe abdominal 
cramping and diarrhea.  Consumption of raw milk and ground beef has been linked 
epidemiologically with several outbreaks of disease caused by E. coli 0157:H7 (31, 87, 152).  
Further outbreaks from consumption of unpastuerized apple juice (75), cheeses (29), lettuce 
(74), bagged spinach (30), and other vegetative products have all been reported.  Increasing 
reported cases of human Escherichia coli O157:H7 illnesses have also been related to contact 
with animals or to water supplies contaminated by runoff from cattle farms.  E. coli O157:H7 
was first recognized as a cause of illness in 1982 during an outbreak traced to contaminated 
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hamburgers.  Since then more infections in the United States have been caused by eating 
undercooked ground beef than by any other food (32).   
 Enteroinvasive E. coli.  EIEC are primarily involved in causing Shigellosis, a  
self-limiting infectious disease such as dysentery in humans.  The burden of this disease was 
estimated to 150 million cases and one million deaths per year in developing countries (89).  
Shigellosis is characterized by the destruction of the colonic epithelium provoked by the 
inflammatory response that is induced upon invasion of the mucosa by bacteria.  The overall 
pathogenic schema of EIEC and Shigella species is to invade epithelial cells and induce an 
inflammatory response, leading to the construction of the epithelium.  EIEC invasion is 
mediated by a large plasmid (140 MDa) coding for the production of several outer membrane 
proteins involved in invasiveness.  Similarly to EPEC, EIEC produce a type III secretion 
system key to the invasiveness and virulence against target cells.  By use of this system, as 
well as other secreted virulence proteins, intracellular bacteria move within the cytoplasm of 
infected cells without being exposed to the external environment (66).   
 Diffusely-adhering E. coli.  Similar to the findings of Nataro and Kaper (110) in 
EAEC, DAEC were identified from their diffuse adherence (DA) pattern on cultured 
epithelial HEp-2 as well as HeLa cells (108).  These E. coli strains have been found to be 
associated with urinary tract infections (UTIs) (pyelonephritis, cystitis, and asymptomatic 
bacteria) and with various enteric infections such as chronic watery diarrhea in young 
children (110).  A key virulence factor in DAEC is the production of adhesins.  Three 
adhesins, Afa, Dr, and F1845, are fimbrial adhesins allowing for the diffuse cell adherence to 
epithelial tissues.  Afa and Dr are commonly expressed together and are greatly associated 
with urinary tract infection (134).  Epidemiological studies show that DAEC strains that 
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express adhesins of the Afa/Dr family are involved in 25 to 50% of cases of cystitis in 
children and 30% of cases of pyelonephritis in pregnant women (3, 58).  E. coli expressing 
Dr adhesin has been shown to be associated with a twofold increase in the risk of a second 
UTI, suggesting its possible association with recurrent or chronic UTI (58).  Following 
adhesion to cell surfaces, these adhesins also double as invasins, allowing for entry into  
the intestinal cell lumen as well as macrophages (134).  Another prominent virulence factor 
in DAEC is the flagella.  It has recently been reported that motile Dr and F1845-positive E. 
coli strains were more able to induce an inflammatory response than nonmotile strains (4).  
Destruction and breakdown of the brush-border and severe intestinal inflammation follow 
invasion, and certain DAEC induce apoptosis in invaded cells (57).   
 Enterotoxigenic E. coli.  ETEC is the most common cause of E. coli-mediated  
human diarrhea worldwide (61).  Human ETEC infections are contracted by consumption or 
use of contaminated food and water and are most commonly associated with travel to 
underdeveloped countries.  In addition, ETEC is a major pathogen of animals, being 
responsible for scours in cattle and neonatal and postweaning diarrhea in pigs (126, 155).  
Immediate symptoms include a sudden onset of secretory diarrhea which can lead to 
dehydration due to loss of fluid and electrolytes (118).  ETEC strains follow a specific 
strategy when invading host cells.  First, the bacteria adhere to host cells and multiply.  At 
this time, ETEC strains need to evade host immune defenses.  Strategies for ETEC fitness 
against immune defenses often lead to host damage, such as intestinal lining deterioriation 
(99).  These steps are usually mediated by a number of proteinaceous virulence factors  
called colonization factors.  These factors allow for the direct adhesion to intestinal cells in 
the human and animal digestive tracts (107).  Also, ETEC strains produce one or more 
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plasmid-encoded and heat-stabile enterotoxins that induce a secretory diarrhea.  These toxins 
reduce absorption and increase fluid and electrolyte secretion of small intestinal epithelial 
cells, resulting in severe diarrhea (147).   
Prevalence and Control of E. coli O157:H7 in Meat Products        
 As mentioned previously, cattle are the most common reservoir for EHEC O157:H7.  
The main sources of E. coli infection of cattle during production are contaminated drinking 
water and feed and the immediate environment of the animal.  Risk factors that have been 
identified for infection of animals with E. coli O157 include age, weaning practices, 
movement of the animals, season, feed composition, and the ability of the bacteria to persist 
in the environment (55).  Carcass and meat contamination of E. coli O157:H7 can occur from 
animal contact, as well as unsanitary conditions during transport, lairage, and slaughter.  A 
critical point for controlling the contamination of meat with E. coli O157:H7  is proper and 
hygienic removal of cattle hides.  A recent review by Arthur et al. (5) found that due to cattle 
transport conditions, the prevalence of E. coli O157:H7 on hides increased from 50.3 to 
94.4% between the time cattle were loaded onto tractor trailers at the feedlot and the time 
hides were removed in the processing plant.  In that study, carcasses were swabbed prior to 
transport and lairage as well as directly prior to slaughter.  E. coli isolates were typed using 
pulse-field gel electrophoresis to evaluate differences in strain prevalence over time.  
Interestingly, only 29% of the E. coli O157:H7 isolates collected post-harvest matched those 
isolates collected before transport.  These data indicated that a significant increase in O157 
prevalence accompanied an increase in strain differentiation and abundance.  Combating 
populations of various O157:H7 strains with differing fitness and/or antimicrobial resistance 
capabilities could be extremely difficult.  It is therefore crucial to minimize the amount of E. 
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coli O157: H7 on cattle hides before slaughter.  Cattle can shed E. coli O157:H7 in their 
feces at concentrations as high as 106 CFU/g (124), which can then cross-contaminate 
adjacent carcasses and product surface areas.   
 In the United States during 1992 and 1993, outbreaks of Escherichia coli O157:H7 
infection associated with human consumption of ground beef caused hundreds of illnesses 
and four deaths (148).  As a result of these and like outbreaks, the U.S. Department of 
Agriculture Food Safety and Inspection Service (USDA-FSIS) mandated the Cattle Clean 
Meat Program and zero-tolerance standard regarding the complete removal of fecal material, 
ingesta, and udder fluids from beef carcasses, as well as detectable growth of E. coli 0157:H7 
(149).  Although these standards have long been in place, outbreaks continue to occur in 
comminuted products such as ground beef as well as in marinated steaks (92, 152).  E. coli 
O157:H7 contamination occurring during slaughter carries over into fabrication and retail 
products.  E. coli O157 can be attenuated at temperatures between 55–70°C (84); however, 
product remains uncooked during fresh meat production.  Continuous addition of 
antimicrobials throughout the processing facility would presumably inhibit E. coli O157 
contamination; however, this would be expensive and time-consuming.  Also, a recent survey 
by Srinivasan et al. (138) analyzed ~130 isolated E. coli O157 strains from various animal 
reservoirs.  All E. coli isolates exhibited resistance to five or more antimicrobial agents, and 
the majority of isolates carried one or more target antimicrobial resistance genes in different 
combinations.  Even in combination, antimicrobials would not fully prevent further growth in 
fresh meat products.  
 Although not widespread, E. coli O157:H7 has also been associated with swine and 
pork products.  Booher et al. (14) reported that in pigs experimentally dosed with E. coli 
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O157:H7, these strains persisted in the alimentary tracts for up to two months 
postinoculation.  The authors concluded that the data indicated that swine were potential 
reservoirs for E. coli O157:H7.  Supporting that conclusion, Doane et al. (45) stated that 
8.9% of swine rectal samples taken for a large survey study were positive for E. coli 
O157:H7.  No major outbreaks with retail pork product have been reported; however, a 
recent family outbreak of Escherichia coli O157 infection was microbiologically associated 
with consumption of dry-fermented salami made with pork meat only (38).  
 It seems logical to target on-farm contamination in cattle to reduce further 
contamination.  This strategy has proven extremely difficult since E. coli O157:H7 infection 
may not provide clearly visible symptoms or signs to alert the producer or caretaker.  
Callaway et al. (23) stated that fecal shedding can be very sporadic with an animal testing 
positive for EHEC one day but not again for several days or weeks.  An ideal, though 
technologically and physically unfeasible, solution would be to somehow effectively identify 
infected cattle and treat them away from the rest of the herd.  Instead, researchers are 
focusing on the following antimicrobial intervention strategies that can be applied in a 
whole-herd scenario and be effective throughout movement from production to slaughter.   
 Probiotics—competitive exclusion.  Fuller (60) described competitive exclusion (CE) 
as “the addition of exogenous bacteria to the intestinal tract of the animal in order to reduce 
colonization or decrease existing populations of pathogenic bacteria in the gastrointestinal 
tract” (p. 367).  Historically, CE was not considered a viable technique for cattle because of 
the size and environment of the rumen and the length of feeding time associated with cattle 
production.  However, recent research has demonstrated that CE and other probiotics could 
be effectively used to reduce E. coli O157:H7 and other bacteria in cattle (163, 164).  
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Commonly referred to as “direct-fed microbials,” probiotics such as Lactobacillus 
acidophilus (117) and  Propionibacterium freudenreichii (51) have been shown to directly 
reduce E. coli O157:H7 prevalence when fed to cattle.  When feeding L. acidophilis at a level 
of 109 CFU/steer, E. coli O157:H7 was reduced by 30% compared to untreated controls 
(156).  Along with maintenance of intestinal homeostasis, production of antimicrobial 
compounds, promotion of gut barrier function, and immune modulation, competitively 
excluding and controlling E. coli O157:H7 can be added to the attributes of direct-feeding 
probiotics.   
 A similar approach has been taken by direct-feeding strains of bacteria that produce 
bacteriocins.  Bacteriocins are proteins produced by and effective against the producing 
strain of bacteria and like species.  Certain E. coli species produce bacteriocins called 
“colicins.”  Schamberger et al. (130) described the use of a colicinogenic strain of E. coli fed 
to beef cattle to control E. coli O157:H7 shedding during production.  Cattle were first given 
a feed additive containing 8 strains of colicinogenic E. coli at a level of 107 CFU/gram of 
feed.  The cattle were orally inoculated with nalidixic acid-resistant E. coli O157:H7 strains 
seven days after the treatment started.  Over a feeding period of 200 days, the colicinogenic 
E. coli additive was continuously fed at a level of 108 CFU/gram of feed.  During the last 30 
days on test, calves again were challenged with E. coli O157:H7.  Microbiological assays on 
fecal samples indicated a 25% decrease in E. coli O157:H7 shedding when cattle were fed a 
colicinogenic “probiotic.”  Similar results were reported by Zhao et al. (164) and in weanling 
calves by Tkalcic et al. (145).  
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 Bacteriocins and bacteriophage.  Although no work has been reported on the  
use of these cultures on retail product or carcasses, bacteriocins themselves are being 
evaluated for these purposes.  Zhang and  Mustapha (162) compared the use of the 
Lactococcus-produced bacteriocin nisin, either alone or with EDTA, on E. coli O157:H7 in 
vacuum-packaged cubed beef.  The beef cubes were inoculated with 7 log CFU/mL of E. coli 
O157:H7 and dipped in control solutions of 350µg nisin or 350µg nisin with EDTA.  After 
30 days at 4°C, only marginal amounts (<1 log CFU/mL) of E. coli were inhibited.  A more 
convincing experiment analyzed bacteriocins of Pediococcus acidilactici K10 combined  
with organic acids against E. coli O157 in broth culture as well as in ground beef.  When 
combined with 0.35% lactic acid, this bacteriocin inhibited E. coli O157 growth by 2.8 log 
CFU/g of sample (102).  Several reports have shown that certain colicins can be effective 
against E. coli O157 in-vitro (24, 131); however, limited work has been done with these 
bacteriocins on beef products (1).      
 Bacteriophage are viruses that specifically infect bacteria and are common members 
of the intestinal microbial flora of food animals.  The ability of certain bacteriophages to 
infect and kill or inhibit E. coli O157:H7 has been well documented (6, 91, 136).  The ability 
of bacteriophages to kill E. coli O157 in vivo is a different matter; bacteriophages specific 
against E. coli O157:H7 have been repeatedly applied to both sheep (22) and beef cattle (6), 
minimally reducing concentrations of E. coli O157.  Although much work needs to be done 
in the in vivo efficacy of bacteriophages as an intervention strategy, factors such as their 
history of safe use, host specificity, and host-replication strategies provide a solid foundation 
against E. coli O157 colonization (79).   
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 Organic acids.  The most widely researched area concerning beef cattle and 
microbiological control is at the carcass spray and wash stage of processing.  Various 
treatments have been designed to decontaminate beef carcasses including the use of 
sanitizing agents such as hot water or organic acid sprays.  Today, the most common carcass 
intervention is the use of organic acid sprays in which several acids are combined and 
sprayed at several points throughout hot processing.  With the use of multiple or “hurdle” 
antimicrobials, carcasses have an average overall reduction in surface contamination by  
30% and up to two log cycles (16).  Organic acids are commonly used in the slaughter 
environment to reduce pathogen loads on carcasses but are not commonly used in fabrication 
or ground beef facilities.  An interesting experiment by Harris et al. (70) validated the use of 
organic acids and acidified sodium chlorite (ASC) to reduce E. coli O157:H7 in beef trim and 
ground beef in a simulated processing environment.  The data indicated that all antimicrobial 
interventions reduced the level of pathogens to a nondetectable level when challenged with a 
low-level inoculum but were not efficient at levels over 1 x 104 CFU/g.  They also reported 
that organic acids applied at the 2% level or ASC applied at 1,200 ppm could be effective 
interventions for ground beef processors, although these levels were negatively associated 
with sensory acceptance.   
 Prior to carcass washing, organic acids are being proposed as on-farm strategies as 
well.  Contaminated drinking water is an important area of control.  Research targeting water 
intake reservoirs as a preharvest intervention strategy has been analyzed.  The use of 
different chemical treatments including lactic acid, acidic calcium sulfate, chlorine, chlorine 
dioxide, hydrogen peroxide, caprylic acid, ozone, butyric acid, and sodium benzoate were 
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effective at reducing populations up to five log cycles when applied at 100ppm of water fed 
to cattle (165).   
Listeria Monocytogenes    
 Listeria monocytogenes is a facultative, intracellular, gram-positive pathogen that 
causes the human disease listeriosis.  L. monocytogenes is one of the six species of Listeria 
currently recognized, which also include L. innocua, L. seeligeri, L. welshimeri, L. ivanovii, 
and L. grayi.  Although ubiquitous in the environment, Listeria infection is relatively 
uncommon.  It is estimated that L. monocytogenes causes approximately 1,600 listeriosis 
cases annually resulting in 400 to 500 deaths (63).  L. monocytogenes can cause a variety of 
diseases including meningitis and septicemia (56, 94).  L. monocytogenes has been found in 
raw milk, soft cheese, fresh and frozen meat, poultry, and seafood products, as well as in 
fruits and vegetables (32).  One reason for L. monocytogenes’ wide range of habitat is that 
this organism also inhabits wild animals and birds, insects, soil and waste water, as well as 
decaying vegetation (120).  The soil and water habitation directly relates to its existence in 
foraging livestock such as cattle and sheep.  Therefore, humans, as well as animals, can  
contract listeriosis by foodborne contamination.   
 Listeria infection begins by intestinal colonization.  From the intestinal tract, the 
organism invades tissues such as female placenta and liver.  L. monocytogenes is an 
intracellular pathogen, meaning it must first enter susceptible cells and be able to replicate.  
The bacteria produce a cholesterol-dependent cytolysin called Listerolysin O (LLO), which 
allows for escape from phago-lysozomal membranes and bacteria growth in the cytoplasm of 
infected cells including macrophages.  Other virulence proteins function as invasins and 
internalins, specific for entry into epithelial cells.  L. monocytogenes actively multiplies and 
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moves from cell to cell throughout bodily tissues by a highly orchestrated mechanism.  Once 
inside the cytosol, an L. monocytogenes surface protein ActA propels the organism towards 
the cytoplasmic membrane by facilitating the polymerization of actin.  ActaA spans both the 
bacterial membrane and the peptidoglycan cell wall and aids in the formation of actin tails 
that “push” the bacterial cell towards the outside of the cell (119).  The bacteria travel from 
cell to cell by the formation of a filopodium, which is absorbed by an adjacent cell, thus 
repeating the process (80).   
 The ability of L. monocytogenes to survive and grow in a wide variety of cell types as 
well as travel through the circulatory system is the critical characteristic allowing for 
listeriosis to ensue.  Highly susceptible individuals to listeriosis are pregnant or postpartum 
women, fetuses and newborn children, and elderly and/or immunocompromised individuals.  
Symptoms include fever, muscle aches, and sometimes gastrointestinal symptoms such as 
nausea or diarrhea.  Listeria monocytogenes infection can spread to the central nervous 
system, and those symptoms would include headache, stiff neck, confusion, loss of balance, 
or convulsions (33).  Listeria are readily killed by pasteurization and cooking; however, in 
certain RTE foods such as hot dogs and deli meats, contamination may occur after cooking 
but before packaging.  As a precaution, the Centers for Disease Control (CDC) suggest that 
high-risk individuals heat all RTE  foods (e.g., deli meats, frankfurters, etc.) prior to eating 
and avoid eating soft cheeses made from unpasteurized milk and refrigerated meat spreads 
given the prevalence of L. monocytogenes in these products (33).  
Prevalence and Control of L. Monocytogenes in Meat Products        
 Even though the statistics show that the incidence of listeriosis has declined, 
outbreaks and contaminated product recalls continue to occur (32).  A multi-state outbreak of 
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L. monocytogenes occurred in the United States in 2002.  Consumption of contaminated 
turkey deli meat resulted in 46 culture-confirmed cases, seven deaths and three fetal deaths in 
eight states (67).  L. monocytogenes can grow over a temperature range of 1–45°C and a pH 
range of 4.1–9.6.  Also, these pathogens are remarkably stable against acid and osmotic shifts 
(62).  Given these characteristics, RTE foods and manufacturing facilities are a prime 
reservoir for L. monocytogenes colonization.  These products are typically high in salt with a 
low pH, and most are kept at refrigeration temperatures, all conditions which are appealing to 
psychrotropic L. monocytogenes.  The ability to persist in food-processing environments and 
multiply under refrigeration temperatures makes L. monocytogenes a significant threat to 
public health. 
 Currently, FDA has a zero-tolerance policy in place for L. monocytogenes in RTE 
foods.  Based on this policy, the presence of any level of L. monocytogenes in the food 
constitutes adulteration.  Although no single infectious dosage has been reported, several 
murine studies have shown that minimal concentrations (1 log CFU/mL) of L. 
monocytogenes corresponded to susceptibility in immunocompromised subjects (65).  A 
wide variety of intervention strategies are being introduced and evaluated in the manufacture 
of RTE foods including organic acids, irradiation, bacteriocins, and plant extracts.  
 Competitive exclusion.  As in E. coli O157 intervention, the use of probiotic bacterial 
cultures has recently been shown to support anti-listerial strategies in RTE meats.  Amézquita 
and Brashears (2) analyzed Pediococcus acidilactici, Lactobacillus casei, and Lactobacillus 
paracasei on their anti-listerial effectiveness in frankfurters and cooked ham.  Bacteriostatic 
activity was observed in cooked ham, whereas bactericidal activity was observed in 
frankfurters.  Numbers of L. monocytogenes were 4.2 to 4.7 log10 and 2.6 log10 cycles lower 
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than controls in frankfurters and cooked ham, respectively, after the 28-day refrigerated 
storage at 4°C.  It is important to note that due to the zero-tolerance policy, an inhibition of at 
least one log cycle could be efficient at controlling L. monocytogenes contamination.  In 
other studies where lactic acid bacteria was used to competitively exclude L. monocytogenes, 
sensory data indicated no difference in preference of treated cooked ham compared to 
untreated control slices (151).  One aspect to these CE experiments was that all probiotic 
cultures were lactic acid bacteria, and several were isolates obtained from RTE products and 
recultured.  
 Organic acids and other chemical antimicrobials.  The largest area of L. 
monocytogenes control has been placed on organic acids and salts (10, 64).  The most critical 
area of contamination in RTE meats is during post-processing procedures such as peeling, 
slicing, dicing, and packaging.  Many meat processors are currently adding sodium or 
potassium lactate (up to 2%) in combination with sodium diacetate (0.05–0.15%) to product 
formulations (146).  Studies have also shown that antimicrobials—such as other organic 
acids or their salts—applied as immersion or spraying solutions alone, in combination, or 
sequentially can also potentially control L. monocytogenes contamination on RTE meat 
products during storage (8, 127)  Sodium, potassium, or other salts of lactic, acetic, and other 
organic acids have had significant antimicrobial activity against L. monocytogenes in broth 
and in meat products (10, 21, 50).  Although organic acids have been effective anti-Listeria 
agents, the concentrations required for this activity are extremely high.  In several studies, L. 
monocytogeneson RTE meat products survived in refrigerated storage despite the presence of 
organic acids that have bacteriostatic activity against L. monocytogenes (10, 95).  Further 
limitations to the use of organic acids are their variable efficacy and objectionable sensory 
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attributes.  The antimicrobial activity of these acids is dramatically influenced by the 
presence of other antimicrobials or other ingredients commonly used in RTE meat 
manufacture, usually by lowering efficacy (8, 10, 36), and studies have indicated that RTE 
meat products formulated or treated with organic acids had lower overall consumer 
acceptability compared with untreated products.   
 Bacteriocins.  In the hopes of overcoming the limitations of organic acids, 
bacteriocins are being examined as potential interventions for L. monocytogenes control on 
RTE food products (37, 81).  One such bacteriocin, nisin, inhibited growth of L. 
monocytogeneson the surface of bologna by 2.4 to 3.8 log CFU/cm2 at a concentration of 125 
µg/ml (64).  Enterocin, another gram-positive bacteriocin of the pediocin family, has reduced 
L. monocytogenes in broth culture by 3 log CFU/ml when added at 4 µg/ml (53).  Other 
pediocins have had variable antilisterial activity, ranging from 0.5- to 4-log reductions when 
added at concentrations greater than 500 µg/ml to RTE deli products (10).  Bacteriocins, 
being proteinaceous, could lose efficacy over the manufacturing process, such as during 
thermal processing and cooling.  A possible solution to this would be simply to only use 
bacteriocins as post-processing strategies.  A film-based  bacteriocin application was 
demonstrated by Ercolini et al. (54).  These researchers formed active polythene films, coated 
with a solution of bacteriocin 32Y from Lactobacillus curvatus, and tested the capacity in 
which the film could inhibit growth of L. monocytogenes.  The results showed that the direct 
contact between active film surface and L. monocytogenes cells was effective for a fast and 
irreversible inactivation of the bacterial population and could be used to package RTE meats.   
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Part 2.  Bacteriocins 
Introduction to Bacteriocins 
 Bacteriocins are peptides produced and/or secreted by bacteria that possess 
antimicrobial properties towards the producing bacteria, as well as like species.  Bacteriocins 
differ from most therapeutic antibiotics in being proteinaceous and generally possessing a 
narrow specificity of action against strains of the same or closely related species (140).  
Bacteria express, produce, and utilize these proteins for survival and proliferation  
of an organism in a mixed population (47).  Bacteriocins may serve as anticompetitors 
enabling the invasion of a strain into an established microbial community.  They may also 
play a defensive role and act to prohibit the invasion of other strains or species into an 
occupied niche or limit the advance of neighboring cells.  An additional role has recently 
been proposed for gram-positive bacteriocins in which they mediate quorum sensing (98).  
Riley (122) explained that thorough examination of bacteriocins in natural settings, such as 
Lactobacillus plantarum in green olive fermentations, Escherichia coli in guinea pig 
conjunctivae, and Streptococcus mutans in the human oral cavity, have indicated that the 
competitive advantage is substantially increased for bacteriocin-producing cells against 
bacteriocin-sensitive bacteria in the same environments.   
 Bacteriocins were originally defined as bacteriocidal proteins characterized by having 
producer-cell lethal biosynthesis, a very narrow range of activity, and adsorption to specific 
cell envelope receptors (82).  These observations were solely based on E. coli-derived 
bacteriocins, coined “colicins.”  Later, the recognized association of bacteriocin biosynthesis 
with plasmids was added to the description.  The definition has since been modified to 
incorporate the properties of bacteriocins produced by gram-positive bacteria (140).  
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Bacteriocins from gram-positive bacteria commonly do not possess a specific receptor for 
adsorption, although exceptions exist and are most frequently of lower molecular weight and 
overall mass than bacteriocins from gram-negative bacteria, such as the colicins (27, 42, 
123).   
 Gram-negative bacteriocins.  All gram-negative bacteriocins are large proteins 
usually comprising 449 to 629 amino acids.  Gram-negative bacteriocins generally have three 
“modes of action,” which include DNAase or RNAase activity or pore formation in the cell 
membrane (123).  Colicins, a large bacteriocins family produced by E. coli species, will be 
discussed in length in part three of this review.  
 One common event found in gram-negative bacteriocin production is the lethality 
effect of the producing cell.  The bacteriocin is generally produced and released, which 
causes cell death.  These three events are all directed by the bacteriocin lysis protein, also 
expressed and produced by the host cell (27, 85).  
 Regardless of expression locale, bacteriocins isolated from gram-negative bacteria 
appear to have been created by recombination between existing bacteriocins (19, 125).  Such 
frequent recombination is facilitated by the domain structure of bacteriocin proteins.  All 
gram-negative bacteriocins have the same three-domain structure in which: (a) a central 
domain is involved in the recognition of specific cell surface receptors, (b) the N-terminal 
domain is responsible for translocation of the protein into the target cell, and (c) the third 
domain of the protein houses the killing domain and the immunity region, which is a short 
sequence involved in immunity protein binding.   
 Gram-negative bacteriocins such as colicin E1 (115), Colicin N (24), Microcin 24 
(59), and PsVP-10, isolated from Pseudomonas species (113), have all been shown to be 
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active across bacterial groups in a wide variety of applications.  Gram-negative bacteriocins 
show particular affinity for gram-negative bacteria associated with raw and processed meat.  
Due to the large population of enteric bacteria in the gastrointestinal tract of humans and 
animals, these bacteriocins have also been used as dietary additives.   
 Gram-positive bacteriocins.  To date, many more gram-positive bacteriocins have 
been identified than gram-negative.  They differ from gram-negative bacteriocins in two 
fundamental ways.  First, bacteriocin production is not necessarily the lethal event it is for 
gram-negative bacteria.  Also, gram-positive bacteriocins have evolved bacteriocin-specific 
regulation, whereas bacteriocins of gram-negative bacteria rely solely on host regulatory 
networks (123).  The most researched gram-positive bacteriocin family is that of the lactic 
acid bacteria.  There are several classes of these bacteria, all differing in amino acid 
composition, structural composition, and mode of killing.  Bacteriocins are classified into 
separate groups such as the lantibiotics or “lanthionine-containing peptide antibiotics” (Class 
I); the small (<10 kDa) heat-stable post-translationally unmodified non-lantibiotics (Class 
II)—which is further subdivided in the pediocin-like and anti-Listeria bacteriocins (subclass 
IIa); the two-peptide bacteriocins (subclass Ilb); and the sec-dependent bacteriocins (subclass 
IIc); and the large (>30 kDa) beat-labile non-lantibiotics (Class III) (88).  
 Production of bacteriocins in gram-positive bacteria is generally associated  
with the shift from log phase to stationary phase, as well as a direct result of bacterial  
SOS response initiated by environmental stress.  Nisin production begins during mid-log 
phase and increases to a maximum as the cells enter stationary phase (20).  The regulation  
of expression is not cell cycle-dependent per se, but rather culture density-dependent.  It  
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has been demonstrated that nisin acts as a protein pheromone in regulating its own 
expression, which is controlled by a two-component signal transduction system typical of 
many quorum-sensing systems (46).   
 It was first documented that gram-positive bacteriocins exerted their antimicrobial 
effect via membrane disruption.  Recent work suggest that several different mechanisms 
work in concert to either create pores in membrane walls, unravel the peptidoglycan 
synthesis pathway, as well as dissipate the bacterial cell’s protein motive force (72).  Hasper 
et al. (71) visualized the effect of nisin on giant unilamellar vesicles (GUVs) doped with 
fluorescently labeled lipid II.  Lipid II is a biosynthesis molecule that it is essential for the 
transport of cell wall subunits across the bacterial cytoplasmic membrane of bacteria.  These 
images and further research concluded that nisin was actually displacing this essential 
molecule from its functional location in gram-positive bacteria.  Nisin binds to the 
pyrophosphate of lipid II, and their effect depends on the combination of the length of the 
peptide and the thickness of the lipid bilayer.  Previously, nisin was thought to be a  
pore-forming bacteriocin; this detailed experiment proved a different strategy used by nisin 
against target bacteria. 
 Gram-positive bacteriocins such as nisin, pediocin (34), and enterocin (111) have all 
been shown to have extremely broad killing effects against target bacteria.  The conventional 
wisdom about the lethality of gram-positive bacteriocins is that they are restricted to killing 
other gram-positive bacteria.  The lethality can vary significantly from relatively narrow as in 
the case of lactococcins A, B, and M, which have been found to kill only Lactococcus, to 
extraordinarily broad.  For instance, some lantibiotics such as nisin and mutacin B-Ny266 
have been shown to kill a wide range of organisms including Actinomyces, Bacillus, 
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Clostridium, Corynebacterium, Enterococcus, Gardnerella, Lactococcus, Listeria, 
Micrococcus, Mycobacterium, Propionibacterium, Streptococcus, and Staphylococcus (104).   
Part 3.  Colicins 
Introduction to Colicins 
 Colicins are bacteriocins produced by and effective against certain strains of 
Escherichia coli and like species.  Colicins are the most well studied of all the bacteriocins 
and are commonly used as a model for bacteriocin evolutionary studies.  Among the colicins, 
there are two main evolutionary lineages which also distinguish the two primary modes of 
killing: pore formation and nuclease activity (122).  The first colicin was identified in 1932 
as a “heat-labile product present in cultures of E. coli V that was toxic against E. coli φ” (27).  
In part three of this literature review, a discussion of varying types of colicins will be 
discussed.  The primary focus will be placed on the pore-forming colicins including the 
expression, release, and mechanistic approach to pore-formation and target cell death of these 
colicins.  Colicin E1, the focus of this dissertation, is a pore-forming colicin. 
 Variations among colicins: expression, mechanisms, and activity against target 
bacteria.  Colicins comprise the most diverse and abundant microbial defense system (123).  
To date, there are five groups of colicins, differing in specific mechanisms against target 
bacterial cells.  These include pore-formation, DNAase, RNAase, protein synthesis 
inhibition, and murein biosynthesis inhibition.  Despite differences in killing mechanisms, 
the activities of these colicins are mediated by specific binding to receptors on target cells.  
The proteins are then translocated across the membrane of the bacteria and inserted into the 
cytoplasm to exert their toxic effect (25).  All colicins exhibit the same tripartite structural 
organization with each of three domains responsible for specific activities.  The central 
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regions of each molecule are the receptor binding domain, which forms unique structures that 
bind to outer membrane receptor proteins (44).  The amino-terminus acts in “unknown” ways 
during the transport of the toxin through the outer membrane of gram-negative bacteria (17, 
26).  Current hypotheses on these “unknown” translocation events involve the associated 
with a system of proteins called Tol or TonB.  These proteins have been shown to be required 
for colicin import (25).  The Tol system is composed of five proteins that form a multi-
protein complex in the cell envelope of most gram-negative bacteria.  The TonB system 
consists of an outer-membrane transporter and three known inter-membrane proteins: TonB, 
ExbB, and ExbD.  Based on their interactions with these protein systems, colicins are divided 
into two groups, group A and group B.  Group A colicins (A, E1 to E9, K, L, N, and cloacin 
DF13) use the Tol system (41), whereas group B colicins (B, D, Ia, Ib, M, V, 5, and 10) use 
the TonB system (43).  A recent literature review by Cao and Klebba (25) tried to elucidate if 
colicins utilize these protein systems solely or bi-functionally with other unknown 
“machinery” for proper colicin translocation.  Cao and Klebba (25) concluded that: 
Our inability to solve the physiological riddles of TonB and Tol now stands as  
the principal stumbling block to the delineation of colicin uptake processes. 
Unfortunately, the exact functions that TonB and the Tol proteins perform in the cell 
envelope and the mechanisms by which they accomplish them remain elusive . . .  
(p. 410)  
The carbon-terminus contain the toxic activities of colicins (9) that either (a) create  
voltage-gated pores in the cytoplasmic membrane (A, E1, Ia, N, B), (b)  digest target cell 
DNA or RNA (E2-E9, D), or (c) degrade peptidoglycan (M), or nuclease activity-mediated 
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inhibition of protein synthesis (E3, D).  This area is under investigation as well since this 
terminus seems to be the most unbiased in terms of target bacteria.  
 All types of colicins are produced by strains of Escherichia coli that harbor a 
colicinogenic plasmid, pCol.  There are two main classes of pCol, Type 1 and Type 2.  Type 
1 is a small plasmid that can be amplified and is mobilizable in the presence of a conjugative 
plasmid.  The Type 1 plasmid encodes mainly colicins of group A.  Type 2 plasmids are 
slightly larger, conjugative, and can transfer other components of the plasmid including the 
colicin operon and other mobilizable plasmids at the time of horizontal transfer (69).  Type 2 
plasmids also generally encode colicins of group B.  Exceptions to the type of plasmid and 
colicin produced have been found where group B colicins are carried by Type 1 pCol 
plasmids (77).  A recent experiment by Schamberger and Diez-Gonzalez (132) provided 
insight into the non-specific nature of colicinogeny exhibited by E. coli.  In that study, 14 
different colicinogenic E. coli strains were individually tested for colicin type using 
polymerase chain reaction (PCR) and specific primers for known colicins.  Each colicin 
strain produced one to five different colicins, and colicins were generally from different 
groups.  For instance, colicinogenic E. coli strain B23 was isolated from cattle, and data 
indicated the presence of colicins B, Ia, Ib and M.   
 Colicins of both group A (Tol-using) and group B (TonB-using) target E. coli cells by 
interacting with specific outer membrane proteins.  In group A, colicins A, E1, and E9 target 
the vitamin B12 transporter BtuB (27).  Several other colicin-target combinations have been 
identified including colicin K to Tsx; U to OmpA; B and D to FepA; and M to FhuA.  Both 
FepA and FhuA are involved in iron transport.   
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 Although colicin translocation across the outer membrane is still poorly understood, it 
is clear that Tol-dependent (group A) colicin translocation likely occurs by a mechanism 
distinct from that of Ton-dependent (group B) colicins.  The main differences between the 
two systems are that the Tol-dependent colicins utilize many proteins to translocate across 
the membrane of target bacteria, while TonB colicins appear to use a single outer membrane 
protein for binding and transport.  Most pore-forming colicins are housed in group A and are 
therefore Tol-dependent, whereas group B is extremely diverse and includes colicins having 
a variety of toxic mechanisms.  It is unclear whether or not pore-formation or effectiveness of 
colicins is increased or aided by use of the Tol system; recent work, however, has shown that 
colicin binding to OmpF (outer membrane protein F), a gram-negative porin, is essential for 
death of the target cell (78).  OmpF is closely associated with the Tol system; therefore, it is 
likely that pore-forming colicins should reside within group A instead of group B.   
 Upon their transport into the periplasm, colicins exert their cytotoxic effects in a 
variety of ways.  Three cytotoxic activities have thus far been found among group A colicins.  
These include a pore-forming ion channel that depolarizes the inner membrane (52), an  
H–N–H endonuclease activity that degrades chromosomal DNA (129), and a ribonuclease 
activity that specifically cleaves either16S ribosomal RNA (15) or specific tRNAs (112).   
For pore-forming colicins, their cytotoxic roles all take place within the periplasm and are 
dependent on the curvature of the lipid bilayer (137).  The pore-forming group permeabilizes 
the cytoplasmic membrane, thereby destroying the cell’s membrane potential.  From  
studies carried out on artificial membranes, it is clear that these colicins form well-defined 
voltage-gated ion channels in target membranes (116).  
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 In contrast, once a nuclease toxin has been translocated across the periplasmic space, 
the task faced by the cytotoxic domain is quite different to that of a pore-forming colicin, 
since the entire enzymatic domain has to cross the cytoplasmic membrane (83).   
 Recent evidence has shown that the nuclease colicins, specifically DNAases, actually 
form channels with their cytotoxic domains that allows for transport into the cytoplasm 
(103).  Nuclease colicins target essential components of a bacterial cell.  In the case of certain 
nuclease colicins such as colicin E3, the target is a single phosphodiester bond in 16S 
ribosomal RNA that results in the inhibition of translation (161), whereas for colicin E9, it is 
thought that non-specific degradation of the chromosome is responsible for bacterial cell 
death (83).  
 It is interesting to observe the differences in activity the types of colicins exert over 
the same target bacteria.  Bradley et al. (18) evaluated the sensitivity of 20 E. coli O157:H7 
strains to colicins A, E2, K, B, D, Ia, V, G, and H.  Colicin G and H inhibited all 20 strains, 
while Colicin E2 and V inhibited 12 and 18 of the strains, respectively.  The remaining 
colicins tested had no effect.  Colicin G and H are now referred to as “microcins” and are no 
longer considered part of the colicin family.  Microcins are gene-encoded antimicrobial 
polypeptides secreted by certain Enterobacteriaceae, but not specifically E. coli (27).  The 
other two active colicins, E2 and V, function as a DNAase and a pore-former, respectively.  
Data from that study also indicated that colicins belonging  to group B were not effective 
against E. coli O157:H7.  Complementing these results was a study by Murinda et al. (105) 
that evaluated 24 colicinogenic E. coli strains producing standard for inhibitory activity 
against 27 diarrheagenic E. coli strains of various serotypes.  In that study, all B-group 
colicins were ineffective at reducing E. coli O157:H7 populations, and colicin V only 
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reduced the populations of two out of the 27 strains tested.  In both of these studies, colicin 
inhibition was employed using an overlay method of E. coli O157:H7 by colicin-producing 
E. coli strains.  A typical colicin inducing agent used in the proliferation and purification of 
colicins is mitomycin C.  In these experiments, mitomycin C was supplied in the overlay 
agar.  Callaway et al. (24) demonstrated that colicin E1, N, and A purified at 98% were lethal 
against E. coli O157:H7 strains in-vitro.  That study indicated that colicin E1 was more 
efficient at killing E. coli O157:H7 than N or A at a level of 0.1µg/mL.  It seems reasonable 
that colicins could be more effective against target bacteria if they are applied in a pure, 
strain-released form.  A more critical evaluation needs to be employed when comparing 
experimental results of colicins when different purities, specific activities, and preparatory 
strategies were undertaken.  
 Colicin E1.  Colicin E1 is a group A, pore-forming colicin produced by and effective 
against Escherichia coli and like bacteria.  Colicin E1 is a product of the gene “cea” whose 
induction is part of the bacterial SOS response (48).  Colicin is produced in large quantities 
as a result of the SOS response, mimicked in laboratory techniques by the use of such agents 
as mitomycin C.   
 Colicin E1 gene clusters contain a third gene which codes for a protein required for 
the secretion of the bacteriocins, the so-called bacteriocin release protein “kil.”  The “kil” 
protein is also referred to as the bacteriocin release protein (BRP) and is a small lipoprotein 
composed of 27 to 35 amino acids.  The main function of the BRP is to promote colicin 
release; concomitantly, they provoke (a) quasilysis, modifications of the structure of the cell 
envelope, (b) activation of OmpLA, the outer membrane phospholipase A, (c) and death of 
the producing cell.   
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 Upon colicin E1 expression and production, the protein accumulates in the  
cytoplasm of the producing cell.  How the colicin BRP allows colicin release has not been 
fully described.  Current research indicates the release protein aids in the formation of  
trans-envelope pores.  The molecule would use these pores to transverse to the outside of the 
cell (96) .   
 While colicin E1 is being expressed and produced, a lysis protein CelA is 
concurrently expressed and produced.  The result of this timely expression results in the 
death of the host cell upon colicin release.  The killing process of CelA against its host is 
unknown.  It seems to be responsible for the shut-off of chromosomal protein synthesis 
reported during colicin induction (28).  As a result, producing cells will lyse upon release of 
the colicin to the extracellular environment    
 In addition to the bacteriocin, the lysis protein, and the BRP, colicinogenic cells 
synthesize an immunity protein which protects the producing cells against the homologous 
bacteriocin.  In the case of pore-forming bacteriocins such as E1, this protein is actually 
conserved on the cytoplasmic membrane of the producer cells.  Instead of providing 
immunity for the cell itself, it instead functions as a protectant against bacteriocins that may 
be targeting the producer cell (150).   
 The first “lethality” step after colicin E1 is released from the producer cell is its 
binding to its target receptor.  Colicin E1 and like pore-forming colicins bind to the E. coli 
outer membrane cobalamin transporter BtuB.  The structure of BtuB in Figure 1 (160) 
consists of a 22-stranded β-barrel with an amino-terminal hatch domain.  At the time of  
this writing, colicin E3, a nuclease colicin that also utilizes BtuB, is the only  
  
31 
colicin-binding protein complex to have been fully crystallized (101).  The initial binding of 
colicin to the membrane is nearly irreversible under some conditions.  The proposed 
explanation for this binding characteristic is that colicin E1 forms an umbrella-like structure 
in which its hydrophobic segment would be inserted into the membrane where it may interact 
with the hydrophobic core of the bilayer, while the other domains, many of which are 
amphipathic, splay out onto the surface while retaining their secondary structure (114).   
 Once in its membrane-bound state, colicin E1 must go through a series of 
orchestrated events that result in pore-formation.  One of the distinguishing characteristics of 
colicin E1 compared to other pore-forming colicins is the “two receptor” theory.  Zakharov 
and Cramer (159) showed that BtuB functions as an initial receptor to bind colicin, and one 
of the Tol system proteins, TolC, functions to support uptake by the membrane.  Artificial 
membrane work in this experiment showed that without interaction with TolC, colicin import 
did not occur.  These authors propose that TolC is positioned on the membrane surface and 
acts as a passage-support, similar to the rung of a ladder, upon which the colicin cross into 
the membrane (160).  
 The initial events associated with the enormous conformational changes undergone 
by the insertion of colicin into membranes have been studied through the interaction of the 
178-residue C-terminal channel domain of colicin E1 P178, with liposome membranes of 
defined lipid composition (158).  In Figure 2, the pathway of colicin E1 P178 is followed 
from binding to insertion into the bilayer.  It appears that when mimicking the environmental 
conditions within cells, colicin E1 binds to its target receptor, becomes irreversibly bound to 
the membrane, unfolds and elongates, and then is able to insert into the membrane to create a 
pore (158).   
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 At this time, the events surrounding pore-formation are not understood.  It is  
known that colicin E1 unfolds on the lipid membrane surface to form a surface-bound  
two-dimensional flexible helical array that is a precursor state to the inserted channel (157).  
The channel domain subsequently inserts into the membrane and forms ion-conducting pores 
that are voltage-dependent (133).   
 It has been documented that the use of purified forms of colicin E1 can be effective 
against pathogenic bacteria such as E. coli O157:H7 at minute concentrations (24, 130, 139).  
Recently, work with colicin E1 has described efficacy against gram-positive bacteria 
including Listeria monocytogenes (115).  Given the necessity of an outer-membrane receptor, 
as well as gram-negative protein complexes such the Tol system, it is intriguing that this 
colicin E1 would be effective against gram-positive bacteria lacking these proteins.   
 When observing the activity colicin E1 has against pathogenic bacteria, it is 
interesting to explore the possibility for use as antimicrobial interventions.  Due to the 
overwhelming emergence of antimicrobial resistance, the ability of these proteins to generate 
resistance is of great importance.  Foodborne pathogens such as Listeria monocytogenes and 
Staphylococcus aureus have been reported to spontaneously mutate and acquire the ability to 
resist nisin (100).   
 Colicin resistance has been evaluated previously (132).  Escherichia coli can resist a 
colicin if the cell is capable of producing the specific immunity protein that neutralizes the 
colicin effect.  Resistance can also occur if an E. coli cell undergoes a mutation in a receptor 
or translocation system that a colicin may use to gain entry into a cell (121).  Schamberger 
and Diez-Gonzalez (132) evaluated 14 colicinogenic E. coli strains against E. coli O157:H7, 
as well as the resistance potential of the treated E. coli O157:H7 strains to colicins.  In that 
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study, the ability to develop colicin resistance against single colicin producing E. coli strains 
was observed, but rarely against multiple-colicinogenic strains.  The authors concluded that 
when using unpurified, colicinogenic E. coli as a probiotic, use of more than one strain would 
limit the onset of colicin resistance.  No studies have demonstrated resistance to purified 
colicin E1 added to culture.   
 The safety of this protein for human consumption is of particular importance for its 
use on food and food contact surfaces.  Murinda et al. (106) compared the cytotoxicity of 
ColE1, nisin, and pediocin in mammalian cell culture and found that ColE1 was significantly 
less cytotoxic than were both nisin and pediocin.  This finding and our evolutionary history 
of exposure to colicins produced by commensal organisms in the human gastrointestinal tract 
(123) suggest that there should be no concerns for the use of this protein as a biopreservative 
in products meant for human consumption. 
 Colicins are an extremely diverse, abundant group of antimicrobial proteins.  
Bacterial responses to stress or an SOS stimulus abundantly provide E. coli strains with a 
selective advantage over other bacteria in mixed populations.  The ability to exploit this 
survival mechanism of bacteria and subsequently produce and purify these antibacterial 
proteins for use in medical, agricultural, or food safety interventions could provide a 
tremendous breakthrough for antibiotic and antimicrobial research and application.   
Part 4.  Colicins and Food Safety 
 The use of antibacterial compounds in livestock, in and on foods, as well as 
applications with food packaging and contact surfaces is an extremely dynamic area of 
bacterial intervention.  In the early 1940s, prominence was placed on the newly synthesized 
sulfanomides, penicillin, and chloramphenicol as bacterial “super killers.”  An inevitable side 
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effect of the use of antibiotics is the selection for, emergence, and spread of resistant bacteria 
including human pathogens.  Not only have bacteria acquired the mechanisms necessary to 
withstand the effects of antibiotics, but to also “share” these acquired traits with other genera 
or species within the host microenvironment via plasmid, transposon, insertion sequence (IS), 
or cassette-mediated gene transfer (11, 135, 153).  The effects of enhanced bacterial 
resistance are many.  Firstly, antibacterial resistance is growing into a multi-drug 
phenomenon where bacteria are inherently resistant to several classes of antibacterial 
compounds (68).  Multiple drug resistant bacteria limit the availability of efficient treatments 
to animals and humans suffering from a bacterial infection or disease with the potential to be 
life-threatening on a global scale (93).  Also of great importance is the fact that conjugation 
and transfer plasmids can occur between bacterial strains of human, animal, and fish origins 
that are unrelated either evolutionarily or ecologically even in the absence of antibiotics (90).  
The phenomenon of antibiotic resistance, coupled with their persistence in clinical and food 
manufacturing settings, poses a giant risk to human and animal health.   
 The “ideal” antimicrobial would be a nontoxic, environmentally stable compound that 
is unable to promote resistance in target bacteria.  This antimicrobial could withstand 
changes in environmental conditions including pH or osmotic shifts, respond to host changes 
in lipid or amino acid profile and concentration, and be effective over long periods of time.  
While this description seems unattainable, colicin E1 could potentially provide protection 
against bacteria while meeting several of these criteria.  
 Antibiotics were long used due to their lack of toxicity towards humans and animals 
when used at correct levels.  While no direct comparison has been made to antibiotics and 
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colicin E1, the toxicity of colicin E1 was reported and discussed by Murinda et al. (106).  In 
these experiments, the gram-positive bacteriocins nisin and pediocin—as well as colicins  
E1, E3, E6, E7, and K—were evaluated for cytotoxicity against cultured simian virus  
40-transfected human colon and Vero monkey kidney cells.  Nisin and pediocin were the 
most cytotoxic bacteriocins tested here, while colicins E1, E3, E7, and K demonstrated little 
toxicity at the levels tested.  The authors concluded from these results that colicins are safe 
and have potential for use as food bio-preservatives.  It seems logical that bacteriocins 
isolated from nonpathogenic bacteria specifically associated with the gastrointestinal tract 
would not be harmful to humans.  Although this paper showed advanced cytotoxic activity 
with nisin, this is the only bacteriocin which has been approved by the World Health 
Organization (WHO) to be used as a preservative in the food industry.   
 With limited toxicity, the next requirement of colicins as food antimicrobials would 
be resistance.  As mentioned in part three, Schamberger and Diez-Gonzalez (132) reported 
the ability of previously colicin-treated E. coli O157:H7 to become resistant to various 
colicins, including colicin E1, over time.  An interesting dynamic of that research was that 
those colicins that E. coli O157:H7 became resistant to were not pore-forming colicins but 
rather nuclease colicins.  No strains evaluated became resistant to colicin E1.  Colicin E1 is a  
pore-forming colicin and has shown efficacy against various strains of E. coli O157:H7 (24, 
139).  More experimental data need to be collected on the resistance assessment of E. coli 
O157:H7, other E. coli species, and bacterial isolates of gram-negative and gram-positive 
groupings to fully elucidate if a resistance mechanism exists.  The apparent lack of toxicity, 
as well as potential avoidance of resistance, builds a strong case for the use of colicin E1 as a 
food safety intervention strategy.  
  
36 
 To show effectiveness over time as well as the ability to withstand environmental 
changes, it is reasonable to look at the effect of colicin E1 when applied in different settings.  
When applied as a feed additive, colicin E1 has shown to be effective and active over a long 
range of time.  Cutler et al. (40) analyzed the effect of colicin E1 against post-weaning 
diarrhea (PWD) in pigs.  Weaned pigs were fed corn-soy pelleted diets that contained either 
0, 11, or 22 mg colicin E1/kg diet.  After two days of being fed the colicin-containing diets, 
all pigs were orally inoculated with 9 log CFU of two E. coli F18 strains that were isolated 
from pigs with PWD.  The animals were evaluated for diarrheal incidence and growth pattern 
over a five-day period.  Control animals had persistent diarrhea that remained until the end of 
the five-day study.  Only one pig in the 22mg group had any indication of diarrhea, and that 
was seen only on the last day of the study.   
 When applied as a feed additive, colicin E1 had to withstand the harsh environment 
of the gastrointestinal tract and be able to exert its bacteriocidal effects in the small and large 
intestines.  Similar effectiveness was seen when colicin E1 was applied as a sanitizing dip in 
packaged deli ham slices.  When evaluated over a fourteen-day period, 10µg colicin E1 was 
able to reduce L. monocytogenes populations by 5 log10 CFU/gm of product.  These slices 
were kept at 4°C, which meant that colicin E1 had to be thermally stable in cold temperatures 
as well (115).   
 The ability to produce and purify this compound could be the factor that pushes this 
protein into the industry.  Stahl et al. (139) has recently explained the use of ultra-filtration 
and ion exchange chromatography to obtain a purified (98%) quantity of colicin E1 at a 
reduced cost.  Advances in this system, as well as commercially produced methods, could 
provide a cost effective approach at producing large amounts of colicin in a short period of 
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time.  Keeping in mind the low doses required for pathogen reduction, being able to purchase 
large amounts of extremely pure colicin could be beneficial in terms of industry cost.   
 Further application research needs to be done marrying colicin E1 to use in foods  
and animals, but at this time the preliminary research provides a solid ground for continued 
development of this product.  Thermal stability evaluation at minimal and maximal 
temperatures, food matrix-environment analyses, and optimizing the production and 
purification of a stable colicin E1 product are paramount in the advancement of colicin E1 
for use in the food industry.   
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Figure Legends 
Figure 1.  BtuB, Prokaryotic Vitamin B12 receptor. a) unbound BtuB; b) BtuB bound 
 with Vitamin B12 (red). From Mohanty et al., 2003, with permission. 
Figure 2.  Colicin E1 translocation events. Pathway of the distinguishable structure 
 transitions of P178 in the course of binding to the membrane surface and insertion 
 into the bilayer. Rate constants for defined steps are for pH 4.0, I = 0.1 M and 
 25°C. Copied with permission from Zakharov et al., 1999.   
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 CHAPTER 2.  APPLICATION OF COLICIN E1 AS A CARCASS WASH 
INTERVENTION STRATEGY 
 
 
A paper to be submitted to the Journal of Food Protection 
 
 
Brenda S. Patton1,2, Steven M. Lonergan3, Sara A. Cutler3, Chad H. Stahl3, and  
James S. Dickson2,* 
 
Abstract 
Colicin E1 (ColE1) is a bacteriocin produced by and effective against Escherichia 
coli and related species.  The current study examined ColE1 as a potential carcass 
intervention strategy in controlling the contamination of E. coli O157:H7 on beef carcasses.  
Untrimmed beef round roasts were cut into sample sizes of 12.5 x 7.5 x 2.5 cm with an 
adipose layer covering an entire surface of lean.  Samples were placed on sterile metal hooks 
hung in the same orientation as the tissue would hang on a carcass.  Samples were inoculated 
with 1ml TSB (control) or 1mL TSB, containing 5 log 10 CFU E. coli O157:H7 strain WS 
3062 or WS 3331.  After inoculum attachment, 1mL ColE1 (in doses of 0, 100µg, 500µg) 
and 1mg/mL 10mM Tris, pH 7.6 were sprayed on the samples and allowed to associate for a 
period of 10 minutes.  Samples were evaluated at 0 and 30minutes, and at 1, 2, 3, 4, and 5 
days post spray at 10°C for E. coli O157:H7 inhibition.  
Treatment of samples with 500µg and 1mg ColE1 effectively inhibited E. coli 
O157:H7 growth.  When these doses were applied to the samples inoculated with E. coli  
__________________________ 
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62 
WS 3331, E. coli contamination was reduced by 4 and 7 log10 CFU/cm2, respectively, 
compared to the untreated control samples.  In strain WS 3062, treatment with 1mg ColE1 
significantly inhibited growth of E. coli O157:H7 compared to the untreated control for the 
entirety of the study.  Colicin E1 provided powerful reduction of E. coli O157:H7 as a beef 
carcass spray intervention.  
Introduction 
 In the United States during 1992 and 1993, outbreaks of Escherichia coli O157:H7 
infection associated with human consumption of ground beef caused hundreds of illnesses 
and four deaths (30).  As a result of these and similar outbreaks, the U.S. Department of 
Agriculture Food Safety and Inspection Service (USDA-FSIS) mandated the Cattle Clean 
Meat Program and a zero-tolerance standard regarding the complete removal of fecal 
material, ingesta, and udder fluids from beef carcasses, as well as detectable growth of E. coli 
O157:H7 (31).   
 Cattle are a major reservoir for E. coli O157:H7, and contamination of the beef 
carcass at slaughter occurs during such processes as hide removal and evisceration (2, 3).  In 
an effort to reduce E. coli O157:H7 as well as other harmful pathogenic bacteria, processors 
are incorporating antimicrobial intervention strategies into their slaughter processes.  
Commonly used carcass interventions include trimming, steam vacuuming, steam 
pasteurization, water washes, and organic acid washes (5, 8, 9).  Recent studies have 
demonstrated that combinations of antimicrobial interventions are more effective at reducing 
surface contamination on beef tissue than individual interventions (9, 14, 19).  Of these 
antimicrobial interventions, organic acid washes, such as lactic and acetic acids, are the most 
common.  With the use of multiple or “hurdle” antimicrobials, carcasses have an average 
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overall reduction in surface contamination by 30% and up to 2 log cycles (4, 5, 27).  Current 
drawbacks to the use of organic acids are the increase of acid-resistant E. coli O157:H7, the 
efficacy of these organic acids over the fabrication and retail packaging times, and the 
adverse sensory properties detectable on some fresh meat cuts after organic acid treatment 
(11, 24, 27).   
 Colicins are antimicrobial proteins produced by, and effective against, E. coli and 
other members of the Enterobacteriaceae family (6, 16).  Pore-forming colicins, such as 
colicin E1 (ColE1), function as potent bacteriocidal agents via the formation of depolarizing 
ion channels in the cytoplasmic membrane (17).  Colicins have long been viewed as potent 
killers to E. coli, and more recently to enterohemorragic and shiga-producing strains (7, 23, 
28).  Given the efficacy of these proteins against various E. coli strains in vitro, the objective 
of this study was to examine the efficacy of ColE1 against E. coli O157:H7 on beef tissue.  
The current experiments evaluated the use of ColE1 as a spray to reduce E. coli O157:H7 
populations.   
Materials and Methods 
 Colicin production and purification.  Colicin E1 was produced and purified by the 
method of Stahl et al. (28).  Briefly, ColE1 was produced from an E. coli K-12 strain 
containing plasmid pColE1-K53, obtained from the National Collection of Type Cultures 
(Public Health Laboratory Service, London, UK).  Colicin expression was induced with 
mitomycin C, and the ColE1 was purified from the cell-free supernatant by ion exchange 
chromatography using Q Sepharose (Amersham Biosciences, Piscataway, N.J.) and then 
concentrated and desalted by ultra-filtration across a regenerated cellulose membrane in a stir 
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cell apparatus (Amicon, Millipore, Bedford, M.A.).  The ColE1 preparation used in this study 
was purified to near homogeneity (98% pure).  
 Inhibition study.  For each of the two  E. coli O157:H7 cultures, WS 3331 and WS 
3062, (obtained from FSIS, Beltsville, MD,  isolated from ground beef outbreak), 100 µL of 
frozen stock culture was individually added to 9.9mL of sterile tryptic soy broth (TSB) and 
incubated at 35º C for 24 hours.  These cultures were then diluted 1:100 into fresh TSB to 4 
log10 CFU/mL.  From these cultures 7.9 mL aliquots of each E. coli culture were placed into 
10 mL culture tubes containing either 0, 0.8, 8, or 80µg colicin E1 in 100µl of TSB; 
therefore, the final concentrations of the colicin E1 were 0, 0.1, 1, and 10µg ColE1/mL 
culture.  These cultures were then incubated at 35º C, and CFU/mL of E. coli O157:H7  
was determined initially, after 30 minutes, and hourly for five hours of incubation.  Colony 
forming units/mL were determined by serial dilution and plating in triplicate onto  
sorbitol-Mackonkey agar (sMAC).  Plates were incubated for 24 hours prior to counting for 
CFU determination.  
 Beef sample preparation.  Untrimmed beef outside round roasts (IMPS/NAMP 
171B) were obtained from the Iowa State University Meat Laboratory and processed by 
irradiation to an absorbed  dose of 9 kGy to eliminate naturally occurring  bacteria.  Roasts 
were aseptically cut into sample sizes of 12.5 x 7.5 x 2.5 cm with an adipose layer covering 
an entire surface of lean in order to mimic carcass conditions.  Samples were tempered at 
35°C for two hours to reach temperatures similar to that of beef carcasses directly post 
slaughter (18).  Upon reaching abattoir muscle temperatures, the samples were placed on 
sterile metal hooks and hung in the same orientation as the tissue would hang on a carcass.  
Each sample was separated by a square piece of high-density polyethylene plastic (15 x 15 
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cm) to prevent aerosol contamination from the other organisms during spray treatment.  After 
placement on sterile hooks, samples were directly moved to 4°C to simulate movement 
through an abbatoir.  Tissue  samples were hung in accordance with sampling time, so that 
duplicate samples would be evaluated at 0, 30 minutes, and at 1, 2, 3, 4, and 5 days.  
 E. coli inoculum preparation and addition.  For each of the two E. coli O157:H7 
cultures, (WS 3331 and WS 3062), 100µL E. coli was added to 9.9mL of sterile tryptic soy 
broth (TSB) and incubated at 35º C for 24 hours.  Each culture was then diluted 1:100 in 
fresh TSB to 5 log10 CFU/mL.  The cultures were then transferred into sterile plastic spray 
bottles for sample application.  To ensure that the anticipated inoculation levels were 
obtained, a sample from the spray bottle was serially diluted and plated onto tryptic soy agar 
(TSA) as well as sMAC and incubated for 24 hours at 35°C.  For each sample, 1mL of the E. 
coli inoculum was sprayed on surfaces of the sample.  One mL of culture was sufficient in 
covering all surfaces of the carcass samples.  Inoculated samples were allowed to attach for a 
period of 10 minutes prior to ColE1 addition.  
 Colicin preparation and addition.  Sterile plastic spray bottles were filled with 2mL 
of 10mM Tris (pH 7.6) containing either 0, 100µg, 500µg, and 1mg/mL of ColE1.  A total of 
1mL of these washes, which was sufficient to cover all of the surfaces of the sample, was 
applied to each sample.  After spraying, samples were allowed to stand at room temperature 
for 10 minutes prior to being placed in 10°C refrigeration to simulate movement through an 
abattoir. 
 Bacterial enumeration.  Entire samples (12.5 cmx 7.5 cmx 2.5 cm) weighing 
approximately 1.35 grams were placed in 25mL 0.1% peptone water and stomached (Seward 
Stomacher 3500, Worthing, West Sussex, UK) for 60 seconds.  Samples were then serially 
  
66 
diluted in 0.1% peptone water, plated on both TSA and sMAC, and incubated at 35°C for 24 
hours.  Samples were plated in triplicate for each ColE1 treatment.  
 Statistical analysis.  Broth and carcass experiments were conducted two times.  Data 
were analyzed using the general linear model (GLM) procedures of SAS (SAS Institute, 
Cary, NC).  Colicin E1 dose was considered the fixed effect.  Tukey’s standardized range test 
was used to determine statistical differences (alpha level = 0.01).  Colony forming unit data 
were transformed into log10 CFU/cm2.   
Results 
 Inhibition study.  Figures 1a and 1b indicate inhibition of E. coli O157:H7 WS 3331 
(a) and WS 3062 (b) by various concentrations of colicin E1.  Although colicin E1 
signficantly inhibited growth of E. coli O157 WS 3331 compared to the untreated control, no 
colicin E1 dose provided complete inhibition at any timepoint.  Log10 reductions of 1.25, 
2.25, and 3.75 were observed with treatments of 0.1, 1.0, and 10µg colicin E1/mL, 
respectively.  These results differed from strain WS 3062 in which 10µg colicin E1/mL was 
sufficient to completely inhibit growth throughout the five hours of the experiment.  
 Beef sample study.  Treatment of samples with ColE1 effectively inhibited E. coli 
O157:H7 growth at all applied dosage levels (Figures 2a and 2b).  In both of the E. coli 
O157:H7 strains evaluated, control (0µg ColE1) samples had initial populations of ~3 log10 
CFU/cm2 and grew to a maximum of ~6 log10 CFU/cm2.  Strain WS 3331 appeared to be less 
susceptible to ColE1, as the 100µg dose was unable to significantly deter growth compared 
to the untreated control (Figure 2a).  In this strain, at five days post colicin spray, the 500µg 
and 1mg doses were able to reduce contamination by 4 and 5 log10 CFU/cm2 compared to the 
control samples.  Growth was inhibited below detection limits (1 log CFU/cm2 ) until five 
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days post-spray with a colicin E1 dose of 1mg.  Among the samples inoculated with strain 
WS 3062, treatment with 1mg ColE1 significantly eliminated detectable growth of E. coli 
O157:H7 compared to the untreated control for the entirety of the study (Figure 2b).  
Samples sprayed with 100µg and 500µg ColE1/mL had detectable E. coli growth  
post-application, but had 3 and 5 log10 CFU/cm2 lower E. coli levels, respectively, than the 
control samples at the five day sampling.   
Discussion  
 The use of antimicrobials as an intervention on beef carcasses is well documented (9, 
11, 14).  Cattle are known reservoirs for E. coli O157:H7, and if infected carcasses and hides 
are not properly handled at the time of slaughter, this pathogen can continue to grow and be 
found on beef samples during the fabrication process and into retail products (12, 22).  The 
most prevalent antimicrobial strategy in use in beef processing is the use of combinations of 
organic acids as a carcass intervention strategy.  In modern beef processing plants, 2% lactic, 
acetic, and/or various organic acids are applied to pre-evisceration carcasses via an online 
spray cabinet that warms the lactic acid to approximately 42°C (10).  Treating carcasses with 
0.1–2.0% organic acids has been shown to reduce E. coli O157:H7 populations by 30% and 
up to 2 log cycles (5, 27).  In 1998, Smulders and Greer (27) hypothesized that using organic 
acids in this manner may induce the emergence of acid-resistant pathogens including E. coli 
O157:H7.  Current research has supported this hypothesis as acid-adapted and acid-tolerant 
E. coli O157:H7 are readily found in beef processing facilities using organic acid 
interventions, and the use of organic acids against these E. coli strains can induce further 
acid-adaptation and survival of the pathogen at refrigeration temperatures (24, 25, 29).  In the 
hopes of overcoming the limitations of organic acids, bacteriocins are being examined as 
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potential interventions for E. coli O157:H7 on beef carcasses.  Barboza de Martinez et al. (1) 
reported that the use of nisin, a gram-positive bacteriocin produced by lactic acid bacteria, 
was effective at reducing microbial populations on beef carcasses by  2 log CFU/gram  
when applied at 500µg/mL in combination with 2% lactic acid.  Other bacteriocins such as 
sakacin P and curvacin A have also been shown to be effective against a wide range of 
microorganisms including E. coli O157:H7 if applied in combination with other 
antimicrobials (13).  
 Colicins are highly effective against E. coli O157:H7 (7, 15, 28).  Much of the 
antimicrobial efficacy has been evaluated in vitro.  Recent work on the use of colicins in  
pre-harvest intervention strategies, as well as vegetable applications, is being evaluated.  
Colicins have been fed to beef cattle to prevent E. coli O157:H7 shedding (26), as well as 
being used as a sanitizer in alfalfa sprout washes (21).  These applications have widened the 
potential for colicins against enterhemorrhagic E. coli.   
 Evidence supporting colicin E1 use against E. coli O157:H7 is shown in Figures 1a 
and 1b.  Inhibition of both strains of E. coli O157:H7 was apparent at all doses compared to 
the untreated controls; however, in both strains treating with at least 10µg ColE1/mL 
provided reductions of ~5-6 log10 CFU/cm2.  
 In beef sample study, ColE1 was able to completely inhibit growth—below detectable 
levels—of E. coli O157:H7 on beef samples at a dose of 1mg ColE1 (Figure 2).  In strain WS 
3331, 1 mg ColE1 reduced E. coli O157:H7 to undetectable levels until five days post-ColE1 
application.  After five days, the 1mg ColE1 inhibited E. coli O157:H7 by 5 log10 CFU/cm2.  
Growth of both control treatments reached a level of ~6 log10 CFU/cm2 after five days of 
growth at 4°C.  At first glance, the growth of these E. coli strains seems extremely rapid 
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under the experimental treatments.  One reason for the resulting growth patterns was the 
doubling time of these strains, which we determined to be 16 and 20 minutes for strain WS 
3331 and WS 3062, respectively (data not shown).  Additionally, samples were tempered to 
35°C prior to sampling.  Although samples were moved to 4°C after inoculation, the latent 
heat would be sufficient to allow for continued growth for ~12 hours.   
 These data prove that ColE1 has potential as an effective  antimicrobial carcass spray 
and is at least as effective as other bacteriocins previously evaluated for the same use (1).  
Also, the highest level of ColE1 used in this study (1mg) is more effective against E. coli 
O157:H7 than typically used levels of organic acids.  Smulders and Greer (27) reported that 
organic acids typically reduce E. coli O157;H7 populations by 2 logs.  In this study, at 
certain points colicin E1 was able to reduce E. coli O157 populations by almost 7 log10 
CFU/cm2.   
 While the results demonstrate the efficacy of ColE1 against E. coli O157:H7, the 
safety of this protein for human consumption is also of particular importance for its use on 
food.  There is great support for the safety of ColE1 for use in or on food.  Murinda et al. (20) 
compared the cytoxicity of ColE1, nisin, and pediocin in mammalian cell culture.  In that 
study, ColE1 demonstrated significantly less cytotoxicity than both nisin and pediocin. 
Coupled with the long history of exposure that humans have to colicins produced by 
commensal organisms in their gastrointestinal tract (23), this suggests that there should be no 
concerns for the use of this protein as an antimicrobial carcass spray.  
 Given the limited efficacy of organic acids and the emergence of acid-resistant 
pathogens, there is a critical need for a safe, potent, and effective carcass intervention 
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strategy that will not only improve abilities to meet zero-tolerance requirements for E. coli 
O157:H7 but also guarantee a safer retail product.  
Conclusions 
 Colicin E1 is an effective antimicrobial against E. coli O157:H7.  Treatment with 
ColE1 provided effective reductions against E. coli O157:H7 as a carcass spray intervention.  
While the 500µg/mL dose provided a ~5 log10 CFU/cm2 reduction compared to the untreated 
control samples, dosing with 1mg ColE1 inhibited growth below detection limits for the 
duration of the study.  Further work is needed to identify optimum dose requirements against 
multiple strains of E. coli O157:H7 to understand if inoculum type and level will affect the 
antimicrobial activities of ColE1.  
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Figure Legends 
Figure 1.  Colicin E1 inhibits E. coli O157:H7 in broth culture.  Broth culture   
  evaluation  of WS 3331 (a) and WS 3062 (b) treated with concentrations of  
  colicin E1.  Samples were taken immediately post-application, 30 minutes,  
  and hourly for five hours at 35°C.  ♦ = no colicin (control); □ = 0.1µg   
  colicin E1/mL; ∆ = 1.0 µg colicin E1/mL; X = 10µg colicin E1/mL. 
Figure 2.  The effect of ColE1 against E. coli O157:H7 on beef carcass samples.   
   Beef samples were initially inoculated with 5 log10 CFU/mL of E. coli  
   O157:H7, and treated with 0, 100, 500µL or 1mg of ColE1.  Detectable  
   levels of E. coli WS 3331 (a) and WS 3062 (b) are represented over a five  
  day period at 10°C.  ♦ = 0 (control); □ = 100µg ColE1; ∆ = 500µg ColE1;  
  X = 1mg ColE1.  
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 Figure 2.  The effect of ColE1 against E. coli O157:H7 on beef carcass samples. 
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CHAPTER 3.  INHIBITORY ACTIVITY OF COLICIN E1 AGAINST 
LISTERIA MONOCYTOGENES 
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Abstract 
 Colicins are gram-negative bacteriocins produced by, and effective against, 
Escherichia coli and related species.  Colicin E1 (ColE1) is composed of three functional 
domains, which collectively cause a pore-forming effect on targeted bacteria.  ColE1 binding 
and translocation domains are highly specific in contrast to the pore-forming domain, 
implying ColE1 could be broadly effective.  This study evaluated the activity of ColE1 
against L. monocytogenes in broth and on RTE product surfaces.  Individual strains of L. 
monocytogenes were examined in broth containing 0, 0.1, 1, or 10µg ColE1/mL.  While 
strain differences in sensitivity to ColE1 existed, growth was significantly reduced in all 
strains at doses as low as 0.1 µg/mL. Sterilized ham slices were submerged in a 5-strain 
Listeria monocytogenes cocktail (either 7 log10 CFU/ml or 4 log10 CFU/ml) and placed in 
vacuum packages containing 0, 1, 5, 10, 25, or 50µg ColE1.  Ham slices were then stored at 
4 or 10°C and sampled for presence of L. monocytogenes after 1, 3, 7, and 14 days.    
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 Reduction of L. monocytogenes by ColE1 was dependant on initial inoculum level as 
well as storage temperature.  For slices stored at 4°C, treatment with 25ug reduced Listeria 
growth below detection limits for the 4 log10 CFU/mL inoculum slices for the entire 14d, 
whereas for 7 log10 CFU/mL slices, growth was detected 7d post inoculation.  For slices 
stored at 10°C, ColE1 significantly inhibited growth of L. monocytogenes at the 10µg/mL 
dose up to three days for both inoculums.  These data indicate that ColE1 is highly effective 
against Listeria.  
Introduction 
Listeria monocytogenes is a foodborne pathogen responsible for human listeriosis, a 
severe gastrointestinal illness with a mortality rate of 30% (28).  Numerous cases of 
foodborne illness have been linked to the consumption of RTE (RTE) products contaminated 
with L.  monocytogenes.  Among the many categories of RTE foods, deli meats have been 
identified as products of highest risk for causing listeriosis on both per serving and per 
annum basis (37).  The resilience of this species has allowed for it to be ubiquitous in the 
food manufacturing and processing environments (18).  Listeria  monocytogenes resists the 
deleterious effects of high salt concentrations, pH extremes, freezing, and drying common to 
the manufacture of RTE meat products (22).  Due to the widespread nature of L. 
monocytogenes, RTE products can become contaminated with this pathogen during peeling, 
slicing and repackaging, as well as at the retail and consumer levels during storage and 
preparation.  
In response to this risk, the Food Safety and Inspection Service (FSIS) and the Food 
and Drug Administration (FDA) have set strict regulatory standards for RTE products 
including a “zero-tolerance” for L. monocytogenes on all RTE foods.  Several antimicrobial 
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methods are currently being used, and others are being evaluated for potential application to 
food products and packaging in order to meet these new FSIS standards.  These include but 
are not limited to: steam pasteurization, hot water pasteurization, radiant heating and high 
pressure processing, UV and ionizing radiation, and the application of antimicrobial organic 
acids such as lactates, diacetates, and propionates.  Costs associated with the implementation 
of the currently available methods, as well as their limited efficacy, clearly indicate a critical 
need for a cost-effective intervention capable of reducing high levels of L. monocytogenes on 
RTE products.  
Colicins are antimicrobial proteins produced by, and effective against, E. coli and 
other members of the Enterobacteriaceae family (6, 24).  Pore-forming colicins function as 
potent bacteriocidal agents via formation of depolarizing ion channels in the cytoplasmic 
membrane (25, 31).  Given the efficacy of these proteins against various E. coli strains (32, 
34), we were interested to determine if these bacteriocins could be efficacious against L. 
monocytogenes.  The current study evaluated the activity of Colicin E1 (ColE1) against L. 
monocytogenes in both pure culture and on RTE product surfaces.  
Materials and Methods 
 Colicin production and purification.  Colicin E1 was produced and purified by the 
method of Stahl et al. (34).  Briefly, ColE1 was produced from an E. coli K-12 strain 
containing plasmid pColE1-K53, obtained from the National Collection of Type Cultures 
(Public Health Laboratory Service, London, UK).  Colicin expression was induced with 
mitomycin C, and the ColE1 was purified from the cell-free supernatant by ion exchange 
chromatography using Q Sepharose (Amersham Biosciences, Piscataway, N.J.) and then 
concentrated and desalted by ultrafiltration across a regenerated cellulose membrane in a stir 
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cell apparatus (Amicon, Millipore, Bedford, M.A.).  The purity of the ColE1 preparation 
used in this study can be seen in Figure 1.   
 Broth culture evaluation.  Five isolated strains of Listeria monocytogenes were 
grown and evaluated for sensitivity to ColE1.  The five strains included one human clinical 
isolate (2045 Scott A) and four meat product isolates (FSIS 1126 isolated from a beef 
carcass, H7769 isolated from a RTE poultry product, H7762 and H7764 both isolated from 
frankfurters) all carrying the serotypes (1/2a, 4b) for human clinical illness.  All strains were 
obtained from National Animal Disease Center (NADC, Ames, IA) and the Food Safety 
Research Laboratory, Iowa State, Ames, IA).  Growth curves for the individual strains were 
constructed to determine the time necessary to reach 4 log10 CFU/mL under the growth 
conditions utilized.  For each of the five cultures examined, frozen stock cultures (9.5 log10  
CFU/mL) were thawed at room temperature, and 100µL of the re-suspended stock culture 
was added to 9mL of sterile Trypticase soy broth (TSB, Becton-Dickinson, Sparks, MD) 
containing 0.6% yeast extract (YE, Becton-Dickinson, Sparks, MD) (TSBYE).  Cultures 
were incubated at 37°C for 24 hours, and then 1mL of the culture was placed into 99mL  
of fresh TSBYE and changes in optical density and growth were determined hourly over a  
24 hour incubation.  Optical density was determined at 600nm (Spectronic 20D 
spectrophotometer, Thermo Spectronic Inc., Madison, WI) and growth (CFU/mL) was 
determined by serial dilution and plating onto Modified Oxford Listeria Selective Agar 
(MOX, Becton-Dickson, Sparks, MD) followed by incubation at 37ºC for 24 hours.  
 Colicin sensitivity testing.  For each strain, 100 µL of frozen stock culture was 
individually added to 9.9mL of sterile TSBYE and incubated at 37º C for 24 hours.  These 
cultures were then diluted 1:100 into fresh TSBYE and allowed to grow to 4 log10 CFU/mL.  
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From these cultures 7.9 mL aliquots were placed into 10 mL culture tubes containing either 
0, 0.8, 8, or 80µg ColE1 in 100µl of 10 mM Tris, pH 7.6; therefore, the final concentrations 
of the ColE1 were 0, 0.1, 1, and 10µg ColE1/mL culture.  These cultures were then incubated 
at 37º C and optical density and CFU/mL of L. monocytogenes determined initially and after 
1, 3, and 6 hours of incubation.  Optical density was determined at 600nm, and CFU/mL 
were determined by serial dilution and plating in triplicate onto MOX agar.  Plates were 
incubated for 24 hours prior to counting for CFU determination.  
 Acquired resistance evaluation.  In order to determine if surviving L. monocytogenes 
had altered metabolism or acquired resistance to ColE1, single isolates of L. monocytogenes 
that survived the 10µg ColE1/mL dose in the broth culture study were isolated from the 
MOX plates for each of the five strains tested.  These isolates were then restreaked onto fresh 
MOX agar and allowed to grow at 37°C for 24 hours.  Regrown isolates were then identified 
as L. monocytogenes using AccuProbe® Listeria monocytogenes culture identification tests 
(Gen-Probe Inc., San Diego, CA).  Isolates were then analyzed for growth—in the same 
manner as the original strains—in TSBYE with either 0 (Control) or 1µg ColE1/mL.  Optical 
density and CFU/mL of L. monocytogenes were determined initially and after 1, 3, and 6 
hours of incubation at 37°C.  Optical density was determined at 600 nm, and CFU/mL were 
determined by serial dilution and plating in triplicate onto MOX agar.  Plates were incubated 
for 24 hours prior to counting for CFU determination. Resistance isolation and regrowth was 
repeated three times, with five isolates per strain in each replication.  The original ColE1 
sensitivity testing as well as the acquired resistance growth studies were each conducted on 
three separate occasions.  
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 Ready-to-eat (RTE) product evaluation.  For each of the five stock cultures, 100µL 
was added to 9.9mL of sterile TSBYE and incubated at 37º C for 24 hours.  Each culture was 
then diluted 1:100 in fresh TSBYE and grown to either 4 log10 CFU/mL or 7 log10 CFU/mL.  
Within each inoculum level, 10mL of each culture was transferred into 90mL sterilized 0.1% 
peptone water, and the five individual strains were then combined (450mL total) for 
submerging ham slices.  To ensure that the anticipated inoculation levels were obtained, a 
sample from each pooled inoculum culture was serially diluted and plated onto MOX agar.  
Ham slices were sterilized by irradiation to avoid potential pre-contamination with Listeria or 
other bacteria (15).  Ham slices weighing 50g (surface area of approximately 232cm2) were 
aseptically sliced in half, completely submerged in the five stain L. monocytogenes inoculum 
for 10 minutes to allow for bacterial attachment, then drained briefly, and transferred into 
sterile vacuum bags containing 1mL of various ColE1 doses in 10mM Tris, pH 7.6.  The 
bags were then massaged (Seward Stomacher 3500, Worthing, West Sussex, UK) for 60 
seconds, vacuum packaged, and placed into refrigeration.  Slices stored at 4°C were treated 
with ColE1 concentrations of 0, 1, 5, 10, and 25µg, and sampled at 0, 1, 3, 7, and 14 days.  
Slices stored at 10°C were treated with ColE1 concentrations of 0, 1, 10, and 50µg ColE1, 
and sampled at 0, 1, and 3 days.  For enumeration of L. monoyctogenes, ham slices were 
aseptically cored (surface area =12.5 cm2, 2.5g), and the cores were serially diluted in 10mL 
peptone water, plated on MOX agar, and incubated at 37°C for 24 hours.  All samples were 
prepared in triplicate for each refrigeration temperature-dose-day sampling point. 
 Statistical analysis.  Data were analyzed as a split-plot design using the general linear 
model (GLM) procedures of SAS (SAS Institute, Cary, NC).  Colicin E1 dose, temperature 
treatment (4° and 10°C), and storage time were considered fixed effects.  Tukey’s 
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standardized range test was used to determine statistical differences (alpha level = 0.01).  
Colony forming unit data from the RTE Product Evaluation were transformed into log10 
CFU/cm2.   
Results 
 Broth culture evaluation.  All strains were sensitive to ColE1; however, significant 
variation in strain susceptibility existed (Table 1 and Figure 2).  Significant reductions in  
L. monocytogenes populations were seen in all of the strains tested with inclusion of 0.1µg 
ColE1/mL, with the exception of FSIS 1126, after one hour (Figure 2).  Strain H7762 was the 
most susceptible strain, as 0.1 µg ColE1/mL culture resulted in approximately 3.5 log10 
CFU/mL less L. monocytogenes than in the untreated control after seven hours of growth.  
Even among the more resistant L. monocytogenes strains, 10µg ColE1/mL culture resulted in 
an approximately 3–4.5 log10 CFU/mL reduction in Listeria counts after three hours of 
incubation.  In all strains, the highest dose of ColE1 utilized (10µg/mL) was not able to 
eliminate all of the Listeria in any of the cultures. 
 Acquired resistance evaluation.  All five strains were evaluated for susceptibility of 
regrown isolates to further ColE1 treatment.  In all strains, growth of control isolates was not 
significantly altered from the original strain data, suggesting that no change in growth or 
metabolism occurred after treatment with ColE1 (Figure 3).  Retreated isolates (n = 5) grew 
extremely similar to the original strains treated at 1µg ColE1/mL, and in certain cases 
appeared to have become more susceptible.  In evaluation of strains Scott A and H7769, 
growth of retreated isolates was significantly lower (P<0.01) at six hours post-addition than 
the original strains.  
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 RTE product evaluation.  For the ham slices stored at stored at 4°C, growth of L. 
monocytogenes was reduced at every ColE1 dosage level (Figures 4a and 4b); however, the 
efficacy of the doses was dependant on the initial inoculum level.  Despite this, the 5.0µg 
ColE1 dose was sufficient to reduce L. monocytogenes levels below our limits of detection 
for over 24 hours, regardless of the inoculation level of the ham slices.  When 25µg ColE1 
was applied on ham slices inoculated with 4 log10 CFU/mL (Figure 4b), no Listeria was 
detectable for the entirety of the 14 day study.  Ham slices inoculated with 7 log10 CFU/mL 
had detectable L. monocytogenes growth at this same ColE1 treatment after three days.  In 
the samples inoculated with 7 log10 CFU/mL, ColE1 application at 5, 10, and 25µg still 
caused a 4 log10 CFU/cm2 reduction in L. monocytogenes compared to the control slices at 
the completion of the 14 day study.   
 Ham slices stored at 10°C were used to evaluate the efficacy of ColE1 against L. 
monocytogenes on RTE products stored under insufficient refrigeration (46).  The 10 and 
50µg ColE1 doses eliminated detectable L. monocytogenes for over 24 hours regardless of 
initial inoculum level.  When the ham slices were stored at 10°C (Figure 3c and 3d), ColE1 
significantly (P<0.01) inhibited growth of L. monocytogenes at doses as low as 1µg.  After 
three days storage at this elevated temperature, ham slices treated with 1µg ColE1 had  ~3 (c) 
and ~2.2 (d) log10 CFU/cm2 lower CFU counts compared to the control slices inoculated at 7 
and 4 log10 CFU/mL, respectively.  After three days post-treatment, doses of 10 and 50µg 
ColE1 still significantly reduced the growth of L. monocytogenes by 3 log10 CFU/cm2 and ~4 
log10 CFU/cm2, based on initial inoculum level (7 and 4 log10 CFU/mL, respectively).  There 
were no significant differences between these two doses at any time point over the duration 
of this study.   
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Discussion 
 Listeria monocytogenes is a prevailing environmental pathogen which poses 
tremendous challenges for the RTE food industry.  This pathogen will grow at temperatures 
ranging from 1–45°C within a pH range of 4.1–9.6 and has been documented to survive in 
cured products up to 120 days (22, 27).  Current intervention strategies for controlling  
L. monocytogenes in RTE meat products are the addition of (a) antimicrobials and chemical 
preservatives, which are generally recognized as safe substances (GRAS),  or (b) a 
combination of two or more of these or like compounds (28, 30).  The most common of these 
compounds used to combat L. monocytogenes in RTE products are organic acids and their 
salts (40).   
 Sodium, potassium, or other salts of lactic, acetic, and other organic acids have 
demonstrated significant antimicrobial activity in broth and meat product applications against 
L. monocytogenes (3, 7, 13, 35, 40).  Although organic acids have proved to be effective  
anti-listerial agents, the levels required for this activity are extremely high.  Additionally, 
several studies have shown that L. monocytogenes on RTE meat products survived in 
refrigerated storage despite the presence of organic acids that have been shown to have 
bacteriostatic activity against L. monocytogenes (3, 26, 39).  Further limitations to the use of 
organic acids are their varying efficacy and sensory attributes.  The antimicrobial ability of 
these acids is dramatically influenced by the presence of other antimicrobials or other 
ingredients commonly used in RTE meat manufacture (2, 3, 9, 16, 36).  Current studies have 
indicated that RTE meat products formulated or applied with organic acids led to lower 
overall consumer acceptability compared to untreated products (17).  
  
87 
 In hopes of overcoming the limitations of organic acids, bacteriocins are being 
examined as potential interventions for L. monocytogenes on RTE food products (10, 21).  
One such bacteriocin, nisin, was found to inhibit growth of L. monocytogenes on the surface 
of bologna by 2.4–3.8 log10 CFU/cm2 at a concentration of 125µg/mL (17).  Enterocin, 
another gram-positive bacteriocin of the pediocin family, has been shown to reduce  
L. monocytogenes growth in broth cultures by 3 log10 CFU/mL when included at 4µg/mL 
(14).  Other pediocins have shown varied anti-Listerial activity, ranging from 0.5–4 log10 
CFU/mL reductions when included at concentrations greater than 500µg/mL (1, 14, 20, 36).   
 Based on the efficacy of ColE1 against L. monocytogenes demonstrated in this study, 
it appears that ColE1 is more efficacious against Listeria than any of the previously reported 
bacteriocins.  In our study, ColE1 was effective at reducing L. monocytogenes populations in 
pure culture, significantly reducing growth at doses of 0.1µg/mL (Figure 2).  Among the five 
strains evaluated, reduction levels up to 5.5 log10 CFU/mL were observed with 
concentrations as low as 1µg ColE1/mL.   
 No other research has examined ColE1 for anti-Listerial activity.  Since bacteriocins 
are frequently thought of as a means for similar bacteria to compete with each other for 
resources, it was surprising to see this high level of efficacy of an E. coli derived bacteriocin 
against Listeria.  Colicin E1 exerts its cytotoxicity toward E. coli and other closely related 
bacteria through the formation of ion channels that depolarize the cytoplasmic membrane (8). 
Colicin E1 is composed of three functional domains that collectively cause a pore-forming 
effect on targeted bacteria (11).  In gram-negative bacteria, pore-forming colicins must 
accomplish three tasks: binding to an outer membrane receptor, translocating across the 
periplasmic space, and inserting into the cytoplasmic membrane to form a highly conductive 
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ion channel (12, 31, 38).  For binding and translocation purposes in gram-negative bacteria, 
ColE1 uses the vitamin B12 receptor, BtuB, and members of the Tol and OMP protein 
complexes (4, 11, 19, 33, 38).  Future studies examining binding and attachment sites of 
ColE1 to L. monocytogenes are imperative to elucidating the mechanism of action of this 
bacteriocin against gram-positive organisms.  
 In our RTE product evaluation, significantly lower levels of ColE1 were required to 
reduce growth of Listeria monocytogenes compared to the previously mentioned 
antimicrobial studies (14, 16).  With properly refrigerated ham slices that initially had 
approximately 2.5 log10 CFU/cm2, treatment with 10µg of ColE1 reduced L. monocytogenes 
levels below the detection limits for three days (Figure 4b), and 25µg ColE1 reduced L. 
monocytogenes populations to undetectable levels for the entire 14 day study.  Increasing 
refrigeration temperature from 4°C to 10°C had dramatic effects on product stability as well 
as ColE1 efficacy.  At 10°C, 50µg of ColE1 reduced L. monocytogenes populations by 4 
(Figure 4c) and 3 log10 CFU/cm2 (Figure 4d) compared to the untreated control at three day 
post application (7 and 4 log10 CFU/mL inoculum, respectively).  At this time, levels of L. 
monocytogenes reached approximately 9 log10 CFU/cm2 on control slices.  Common L. 
monocytogenes contamination levels in RTE products have been found anywhere from 1 to 5 
log10 CFU/gram of product (37).  In this study, our lower inoculum level (4 log10 CFU/mL) 
provided initial contamination levels (approximately 4.4 log10 CFU/gram) that would be at 
the higher end of this range.  The ability of minute quantities of ColE1 to eliminate 
detectable L. monocytogenes from a RTE product contaminated at levels above the average 
seen among contaminated RTE products in the industry strongly supports its potential as an 
anti-Listeria agent for use in food.  
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 Further supporting evidence on the value of ColE1 as a potent anti-listerial agent is 
the lack of acquired resistance demonstrated in this study (Figure 3a-e).  Previous studies 
have shown that L. monocytogenes can spontaneously become highly resistant to bacteriocins 
such as nisin and pediocin (5, 23).  
 While we have demonstrated the efficacy of ColE1 against L. monocytogenes, the 
safety of this protein for human consumption is of particular importance for its use on food.  
There is great support for the safety of ColE1 for use in food.  Murinda et al. (29) compared 
the cytoxicity of ColE1, nisin, and pediocin in mammalian cell culture.  In this study, ColE1 
demonstrated significantly less cytotoxicity than both nisin and pediocin.  Coupled with the 
long history of exposure that humans have to colicins produced by commensal organisms in 
their gastrointestinal tracts (32), this finding suggests that there should be no concerns for the 
use of this protein as a biopreserative. 
Conclusions  
 Colicin E1 effectively reduced populations of L. monocytogenes in broth culture as 
well as on RTE meat product surfaces.  While strain differences in sensitivity to ColE1 
existed, growth was significantly (P < 0.01) reduced in pure cultures of all strains tested with 
a ColE1 dose of 0.1µg/mL.  The mechanism of action of ColE1 against gram-positive 
organisms such as L. monocytogenes has not yet been elucidated.  Understanding this 
mechanism could lead to broader applications of ColE1 against many other bacterial 
pathogens.  Colicin E1 is a safe and highly effective anti-Listerial agent, and its application 
to RTE meat products could provide greater safety against L. monocytogenes throughout the 
food processing and retail process.  
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Figure Legends 
Figure 1.  Purity of colicin E1 preparation.  Purity of ColE1 was assessed by  
 SDS-Polyacrylamide gel electrophoresis utilizing a 12% polyacrylamide  
 gel loaded with A: 5µg BenchMark Pre-Stained Protein Ladder   
 (Invitrogen) and B: 30µg Colicin E1 in 10mM Tris, pH 7.6. 
Figure 2.  The effects of ColE1 on Listera monocytogenes in broth culture.    
  Changes in growth (Log10 CFU/mL) were measured at 1, 3 and 6 hrs after  
  treatment with different concentrations of ColE1 added to TSBYE.  Error  
  bars represent SE (n = 3).  Graph A = L. monocytogenes FSIS 1126;   
  Graph B = L. monocytogenes Scott A; Graph C = L. monocytogenes   
  NADC H7769; Graph D = L. monocytogenes NADC H7762; and Graph E  
  = L. monocytogenes NADC H7764.  
Figure 3.  Acquired resistance evaluation of Listeria monocytogenes to ColE1.   
  Changes in growth (Log10 CFU/mL) of previously ColE1 treated L.   
  monocytogenes isolates were measured at 1, 3, and 6 hrs after re-treatment  
  with either 0 or 1µg ColE1/mL.  Error bars represent SE (n = 3).  Graph A  
  = L. monocytogenes FSIS 1126; Graph B = L. monocytogenes Scott A;  
  Graph C = L. monocytogenes NADC H7769; Graph D = L.    
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  monocytogenes NADC H7762; and Graph E = L. monocytogenes NADC  
  H7764.   
Figure 4.  The efficacy of ColE1 against L. monocytogenes in RTE products.    
  Reductions of L. monocytogenes  (Log10 CFU/cm2) on ham slices after  
  treatment with different concentrations of ColE1.  Graphs A and C   
  represent the ham slices originally inoculated with 7 log10 CFU/mL and  
  Graphs B and D represent the ham slices inoculated in 4 log10 CFU/mL.   
  Graphs A and B depict ham slices refrigerated at 4°C for 14 days, and   
  Graphs C and D depict ham slices refrigerated at 10°C for three days.    
  Error bars represent SE (n = 3).
  
97 
 
 
Table 1.  Optical Density (600nm) of Listeria monocytogenes strains 
                treated with ColE1 at 0, 1, 3, and 6 hours.  
 Sampling time (hr) 
 0 1 3 6 
FSIS 1126  
   
     Dose (µg/ml)     
0.00 0 0.008 0.218a 0.712a 
0.10 0 0 0.064b 0.132b 
1.0 0 0 0.027c 0.176c 
10.0 0 0 0.010b 0.117b 
 
    
Scott A 
    
0.00 0 0.050a .325a 1.350a 
0.10 0 0b .223b 0.776b 
1.0 0 0b .303a 0.709c 
10.0 0 0b .218b 0.590d 
     
H7769 
    
0.00 0 .0100 0.154a 1.25a 
0.10 0 0 0.021b 0.061b 
1.0 0 0 0.020b 0.600c 
10.0 0 0 0.130a 0.500d 
     
H7762 
    
0.00 0 0.011 0.057a 1.28a 
0.10 0 0 0.020b 0.100b 
1.0 0 0 0b 0.005c 
10.0 0 0 0b 0.004c 
     
H7764 
    
0.00 0 0 0 0 
0.10 0 0 0.002 0.018 
1.0 0 0 0.002 0.018 
10.0 0 0 0 0.005 
a,b,c,d
 Within a given strain and time point, means not sharing a common 
superscript are significantly different (P<0.01).  
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Figure 1.  Purity of Colicin E1 preparation. 
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 Figure 2.  The effects of ColE1 on Listera monocytogenes in broth culture. 
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Figure 3.  Acquired resistance evaluation of Listeria monocytogenes to ColE1. 
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Figure 4.  The efficacy of ColE1 against L. monocytogenes in RTE products. 
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CHAPTER 4.  ON THE ROLE OF COLICIN E1 AGAINST 
  LISTERIA MONOCYTOGENES 
 
 
A paper to be submitted to Antimicrobial Agents and Chemotherapy 
 
 
Brenda S. Patton1,2, J. S. Dickson2, T. M. Pepper3, S. A. Cutler4, and C. H. Stahl4,* 
 
Abstract 
 Colicin E1 exerts its cytotoxic activity on gram-negative bacteria in a three-step 
process: (a) E1 binds to the outer membrane (OM) receptor, BtuB, (b) translocates across the 
OM using the Tol protein system, and (c) creates a lipid-dependent toroidal pore in the 
cytoplasmic membrane.  These processes rely on proteins conserved to gram-negative 
species.  Recent work has shown that E1 has inhibitory effects against the gram-positive 
pathogen Listeria monocytogenes.  To elucidate the mechanism of lethality which E1 utilizes 
against  L. monocytogenes, cytoplasmic membrane depolarization of L. monocytogenes was 
observed by flow cytometry using the membrane-potential sensitive dye DiBAC(4).  Colicin 
E1 exerted 30% higher rate of membrane depolarization in L. monocytogenes compared to E. 
coli O157:H7.  Cellular leakage was similar in E. coli and L. monocytogenes  treated with 0.1  
and 1.0µg/mL E1.  Colicin E1 was visualized over time within L. monocytogenes cells 
using transmission electron microscopy, using immunocytochemical techniques and  
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gold-conjugated secondary antibodies.  Colicin-E1 was biotinylated, incubated with L. 
monocytogenes and eluted over a monomeric avidin column to capture interactive proteins.  
Fractions were collected, run on SDS-PAGE, and detected via silver staining.  Four distinct 
proteins were analyzed by MALDI-TOF and identified as E1 of E. coli, DNA polymerase III, 
LepA, and Cell wall anchor family protein, of L. monocytogenes.  Association with these 
proteins indicates E1 is acting independently of its recognized mechanism, and acting against 
L. monocytogenes in a novel manner.  
Introduction  
 Bacteriocins are being extensively evaluated for antimicrobial activity and industrial 
applications (7, 9).  Implementation of these bacterially-produced proteins are being used in 
food preservation, medical device sanitization, as well as livestock feed additives (6, 18, 25).  
Colicins are bacteriocins produced by, and effective against, Escherichia coli and similar  
species.  Colicins can be subdivided by their mode of action on target bacteria, including 
pore-formation, nuclease activity against DNA, RNA, and tRNA, as well as protein synthesis 
inhibition (5).  A common characteristic of all colicins is a narrow spectrum of activity, 
generally restricted to E. coli . Colicin E1 has long been known for its effectiveness against 
E. coli serovars (17).  Few bacteriocins are effective across spectrums of bacteria.  The 
mechanism is presence of specific receptors at the surface of the sensitive strains on which 
colicin binds before killing.  Colicins must first bind to a preferential target on the outer 
membrane of E. coli, translocate across the outer membrane, and insert itself into the 
membrane to create a pore, or enter the cytoplasm for nucleic acid destruction.  Mutation of 
the receptor can lead to the loss of sensitivity [resistance] to the corresponding colicin, 
proving the selectivity and necessity of colicin binding (8, 21).  A specific pore-forming 
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colicin, E1 has an orchestrated and well-documented mode-of-action, including binding to 
BtuB, the vitamin B12 receptor of E. coli, translocating across the outer-membrane by the use 
of the Tol protein system, and forming a pore in the cytoplasmic membrane (3, 19, 20, 24).  
Target bacterial cells are killed by membrane depolarization and loss of cellular constituents 
(10).   
 Recent evidence has shown that a colicin E1 has lethal activity against the  
gram-positive pathogen Listeria monocytogenes in broth culture, as well as in packaged deli 
meats (15).  The activity of colicin E1 against Listeria monocytogenes is interesting due to 
the fact that these bacteria lack BtuB, the preferred binding target of colicin E1, as well as 
Tol system of translocation proteins.  
 The objective of this research was to ascertain the mechanistic action of colicin E1 
against the gram-positive pathogen Listeria monocytogenes.  The ability to effectively reduce 
pathogens of a broad nature would be desirable to many uses, including medical, agricultural 
or cosmetic applications.  
Materials and Methods 
Colicin Production and Purification 
 Colicin E1 was produced and purified by the method of Stahl et al. (23).  ColE1 was 
produced from an E. coli K-12 strain containing plasmid pColE1-K53 (National Collection 
of Type Cultures, Public Health Laboratory Service, London, UK).  Colicin expression was 
induced with mitomycin C, and the ColE1 was purified from the cell-free supernatant by ion 
exchange chromatography using Q Sepharose (Amersham Biosciences, Piscataway, N.J.).  
This extract was then concentrated and desalted by ultra-filtration across a regenerated 
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cellulose membrane in a stir cell apparatus (Amicon, Millipore, Bedford, Mass.).  The purity 
of the ColE1 preparation used in these experiments was 98.3%. 
Flow Cytometry   
 Cellular preparation.  Frozen cultures of Listeria monocytogenes (FSIS Strain 1126) 
and Escherichia coli O157:H7 strain 933 (ATCC 43895) were suspended in 99 mL of tryptic 
soy broth containing 0.6% yeast extract (TSBYE), or tryptic soy broth (TSB), respectively.  
Cultures were grown overnight at 37°C, at which point 1mL of each culture was 
resuspended in 99 mL fresh media until reaching exponential growth levels (approximately 
4.0 log10 CFU/mL).  Cells were harvested by centrifugation (10 minutes at 10,000 x g), 
washed twice in 100mM phosphate buffer, pH 7.5, and then resuspended in 9 mL TSBYE or 
TSB.  One mL of each culture was then added to culture tubes containing 0 (control), 2.5, 
1.25, 1.0, 0.6, 0.3, and 0.1µg colicin E1/mL of PBS.  Control and colicin E1-culture mixtures 
were placed in incubation at 37°C, and tested at 1, 5, 10, 15, 25, 30, 45, and 60 minutes.  At 
each time interval, culture tubes were centrifuged for two minutes at 1400 x g, and the 
supernatant was removed by needle vacuum.  Cells were resuspended in 200µL of 100mM 
filtered PBS, and tubes were covered with aluminum foil until cytometric analysis.  
 Cytometic analysis.  Membrane and cytometric analyses were conducted following a 
modified method of Wickens et al. (2000).  The fluorochrome bis-(1,3-dibutylbarbituric  
acid) trimethine-oxonol (DiBAC4) was purchased from Molecular Probes Inc. (Eugene,  
OR).  DiBAC4 was dissolved in 70% ethanol at 1 mg/ml and further diluted in filtered 
phosphate-buffered saline (PBS) to a final concentration of 100 mg/ml. 2.0µL of the DiBAC4 
solutions were added to 180-µL aliquots of the treated or untreated cultures to give final dye 
concentrations of 1.0 mg/ml.  The mixtures were held for one minute in the dark before 
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analysis BD Biosciences FACSCanto™ (BD Biosciences, San Jose, CA) equipped with 17 
mW HeNe 633 nm lasers.  Cell concentration of each sample was approximately 104–105  
CFU/mL.  Dye excitation was achieved at 488nm, and 10,000 events were collected for each 
sample.  Data acquisition and processing were performed using BD FACSDiva™ 4.0. 
(Software from BD Biosciences). The uptake of DiBAC4 is equivalent to loss of membrane 
potential, and data are represented in flow cytometry histograms with gated zones 
representing permealized cells.  These assays were performed a total of four times.  
Cell Permeability 
 Potassium ion leakage.  L. monocytogenes and E. coli O157:H7 cells were grown  
to 4 log10 CFU/mL, harvested by centrifugation (3 min at 3300 x g), and washed with 100 
mM filtered PBS.  Cells were resuspended in either TSBYE or TSB containing either 0 
(control), 2.5, 1.25, 1.0, 0.6, 0.3, and 0.1µg colicin E1/mL.  Culture tubes were held at 37°C 
and analyzed for potassium efflux every five minutes from one to 40 minutes in incubation.  
Colicin E1-induced potassium efflux was monitored using a pH-meter pH 213 (Hanna 
Instruments, Kehl am Rhein, Germany) with a MI-442 potassium electrode and MI-409F 
reference electrode following the method of Orlov et al. (14).  Before each experiment, the 
electrodes were calibrated with standard solutions containing 0.01, 0.1, or 1 mM KCl in 
buffer.  A linear relationship was seen between these concentrations of KCl and measured 
electrode voltage.  Prior to treatment with colicin E1, both L. monocytogenes and E. coli 
O157:H7 cultures were tested for potassium disruption via sonification.  The concentrations 
of K+ in the medium initially (Kinit) and after sonication (Ktotal) were calculated from the 
measured voltages by applying the linear equation (Vmeas = mlog10 [K+] + z) and the 
potassium concentration equation ([K+] = 10Vmeas – z / m).  Calculations of potassium-efflux in 
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percent as % release = ([K+]meas – [K+]init / [K+]total) – [K+]init x 100 (14).  Ion data was 
collected, and regression calculations were performed with the Sigma Plot graphics program 
(SPSS Science, Chicago, IL).  These assays were performed a total of three times. 
 Cellular protein leakage.  Bacterial suspensions were prepared and treated with 
colicin E1 as stated previously.  Culture tubes were incubated at 37°C and measured 
spectrophotometrically (260nm) for protein leakage at 5, 10, 20, 30, 45, 60, 75, and 120 
minutes.  The extent of leaked material in the supernatant fluid was determined in a Unicam 
SP 825 spectrophotometer.  These assays were performed a total of three times.  
 Visualization of Colicin E1 Against Listeria Monocytogenes  
 Cellular preparation.  Cultures of L. monocytogenes (FSIS 1126) were grown, 
harvested, and washed as previously described.  Cells were resuspended in 9 mL TSBYE.  
1mL of each culture was added to a culture tube containing 2.5, 1.0, and 0.1µg colicin E1/mL 
TSBYE.  Culture tubes were placed at 37°C.  At 1, 10, 30, and 60 minutes, samples were 
centrifuged at 2500 x g for 20 minutes to ensure optimal pelleting.  Pelleted cells were fixed 
with 2% glutaraldehyde (w/v) and 0.1% paraformaldehyde (w/v) in 0.1M cacodylate for two 
hours at 4°C.  Samples were rinsed in deionized water and repelleted via microcentrifuge.  
Samples were dehydrated in a graded ethanol series and infiltrated and embedded using LR 
White resin (Electron Microscopy Sciences, Ft. Washington, PA).  Resin blocks were 
polymerized for 48 hours at 4°C under UV light.  Thick and ultrathin sections were made 
using a Reichert Ultracut S ultramicrotome (Leeds Precision Instruments, Minneapolis, MN).  
Ultrathin sections (60–70nm) were collected onto formvar coated nickel grids and held for 
immunocytochemical labeling.   
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 Transmission electron microscopy.  Grids were rinsed gently with deionized water 
and placed in Petri dishes containing moist whatman filter paper (Grade no. 43, Whatman 
plc, Middlesex, UK) and Perafilm (Alcan Packaging, Neenah, WI).  Grids were blocked for 
two hours at room temperature with PBS, pH 7.4.  Grids were then incubated for two hours at 
room temperature with a colicin E1-antibody diluted 1:50 in PBS (pH 7.4) supplemented 
with 2% BSA-c and 0.01% fish gel.  Grids were washed 5 x 5 minutes in PBS incubation 
buffer, pH 7.4.  Gold labeling was carried out by incubating the grids for two hours at room 
temperature with goat-anti-rabbit conjugated to 10nm gold particles (Aurion ImmunoGold, 
Costerwegs, Netherlands) diluted 1:40 in PBS incubation buffer, pH 7.4.  Grids were washed 
4 x 5 minutes in PBS incubation buffer (pH 7.4) and then washed 4 x 5 minutes in deionized 
water.  Images were captured using a JEOL 1200EX scanning and transmission electron 
microscope (Japan Electron Optic Laboratories, Peabody, MA) with a Megaview III digital 
camera (OSIS Pro Software, Olympus Soft Imaging Solutions, Lakewood, CO). 
Target Protein Analysis 
 Biotinylation of colicin E1.  Colicin E1 was biotinylated using the EZ-Link®  
Sulfo-NHS-SS-Biotinylation Kit (Pierce, Rockford, IL).  Ten mg of Colicin E1 in 0.1mM 
Tris-HCL, pH 7.5 was dialyzed into filtered 100mM PBS using Slide-A-Lyzer™ dialysis 
tubes (Pierce, Rockford, IL) for 24 hours.  A 10 mM solution of Sulfo-NHS-SS-Biotin was 
prepared by dissolving 2.2 mg in 360 µl ultrapure water.  To reach a desired level of 1:1 
incorporation, 175µL of biotin was added to each 1mL of colicin E1.  The tubes were 
incubated on ice for two hours, and the samples were then desalted to remove excess biotin 
using a Zeba™ Desalt Spin Column (Pierce, Rockford, IL) and then were assayed for biotin 
incorporation.  Level of biotin incorporation was assessed using the 4´-hydroxyazobenzene-
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2-carboxylic acid (HABA)/avidin cuvette assay.  Briefly, 100µL of biotinylated colicin E1 
were added to 900µL of HABA/avidin solution.  The absorbance (500nm) was read for the 
HABA/avidin solution alone, as well as the mixed cuvette containing the biotinylated colicin 
E1.  Following kit calculations, an incorporation value of 1.5 biotin molecules/colicin E1 
molecule was achieved.  Biotinylated colicin fractions were visualized using western dot-blot 
techniques onto PVDF membranes.  Membranes were incubated with streptavidin-HRP, and 
biotinylated colicin E1 was detected using ECL Plus™ (GE Healthcare Life Sciences, 
Piscataway, NJ).  To evaluate the activity of the biotinylated colicin E1, Listeria 
monocytogenes cultures were prepared as previously described in fresh TSBYE and treated 
with either 0 (control), 1µg/mL of colicin E1, or 1µg/Ml of biotinylated colicin E1.  These 
cultures were plated to evaluate growth on MOX agar, incubated at 37°C, and sampled at  
1, 3, and 6 hours post treatment.  
 Cellular preparation.  L. monocytogenes (FSIS 1126) cells were grown, harvested, 
and resuspended in TSBYE containing 0 or 10µg of biotinylated colicin E1.  Cultures were 
incubated for 45 minutes at 37°C.  At 45 minutes, cells were centrifuged for 30 minutes at 
2500 x g, washed twice with 100mM filtered PBS, and resuspended in a lysing buffer of 
1mM Tris-HCl, pH 8.2, containing 1mg/mL of lysozyme and 1% trichloracetic acid (TCA).  
Cells were lysed for two hours at 37°C and centrifuged for one hour at 2500 x g.  Lysed cells 
were resuspended in 100mM PBS.   
 Affinity chromotography.  Two 2 ml monomeric avidin columns (Immunopure™ 
immobilized monomeric avidin column, Pierce, Rockford, IL) were packed according to the 
manufacturer’s instructions.  Each column contained 2ml of settled gel with an immobilized 
monomeric avidin support coupled to a 50% slurry of 4% beaded agarose.  Each column was 
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washed with 2 x 4 ml of PBS, and then with 3 x 2 ml of biotin blocking and elution buffer (2 
mM biotin in PBS) to block any nonreversible biotin binding sites on the column.  Loosely 
bound biotin from the reversible biotin-binding sites was removed by washing with 3 x 4 ml 
regeneration buffer (0.1 M glycine, pH 2.8) and then with 2 x 4 ml of PBS.  The cell lysate 
supernatant containing biotinylated colicin E1 was added onto one of the columns drop-wise, 
while the control cell lysate supernatant without biotinylated colicin E1 was loaded onto the 
other monomeric avidin column.  After all of the sample solution had been added, 0.25 ml of 
PBS was added to wash the sample completely into the column.  The sample was allowed to 
incubate on the column for 1 hour at room temperature.  The column was washed with 6 x 2 
ml of PBS and fractions collected.  The absorbance of the fractions was monitored at 280 nm 
until all unbound protein was washed off the column.  The bound, biotinylated protein was 
eluted from the column with 6 x 2 ml of the biotin blocking and elution buffer and the 
absorbance of the collected fractions monitored at 280 nm.  In order to elute bound 
biotinylated peptide completely, the column was washed with at least 6 x 2 ml of 
regeneration buffer.   
 Target detection.  Wash and elution samples obtained from the immobilized 
monomeric avidin column were run on 8% SDS-PAGE mini gels (Bio-Rad, Hercules, CA).  
Gels containing wash or elution fractions from each column were loaded and run for three 
hours at 120mV.  Gels were then fixed and stained according to FOCUS Fast Silver™ 
detection kit instructions (G-Biosciences, St Louis, MO).  These assays were completed a 
total of three times. 
 Protein identification.  To identity the  L. monocytogenes proteins associated with 
colicin E1, duplicate silver stained mini-gels (8%) were digested using Investigator 
 111  
 
ProGest™ (Genomic Solutions, Ann Arbor, MI), and the resulting peptides from the 
digestion were analyzed by Matrix Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) on a ThermoBioanalysis Dynamo (TBA, Santa Fe, NM).  Peptide mass and 
peak data were collected using Voyager™ DE Pro 5.0 software.  The calculated peptide 
masses for each experimental sample were compared with masses in the sequence database 
MS-Fit (ProteinProspector v. 4.0.8., UCSF Mass Spectrometry Facility, San Francisco, CA).  
Ms-Fit parameters included the use of NCBInr database and analyzed sequences with a mass 
tolerance of 50ppm.  Experimental mass values higher than 900Da were compared to the 
masses of the microbiological database of NCBInr.  Proteins with the highest percentage of 
masses matched were grouped and identified for each digested protein band.  Cysteine 
carbamidomethylation was considered as fixed modification, and oxidation of Met and 
pyroGlu formation of N-terminal Gln as variable modification.  Identification parameters 
included that the protein must rank at the top two hits with at least six matched peptides, a 
total coverage of over 15%, consideration of protein molecular weight search (MOWSE ≥ 
66).   
Results 
Flow Cytometry 
 Fluorescence of DiBAC(4) is directly attributable to the depolarization of bacterial 
membranes.  E. coli O157:H7 cells treated or untreated with colicin E1 are depicted in  
Figure 2a-b.  After 60 minutes of incubation at 37°C, 57% of the initial sampling  population 
of E. coli O157:H7 had been depolarized by 1.0µg/mL of colicin E1.  Similar results were 
observed in L. monocytogenes (Figure 3a-f).  At 30 minutes of incubation, 17 and 32% of the 
initial L. monocytogenes populations were depolarized by 0.1 and 1.0µg/mL of colicin E1, 
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respectively.  At 60 minutes, 55 % of initial L. monocytogenes populations were depolarized 
by 0.1µg/mL colicin E1, and 89% were depolarized by 1.0µg/mL.  There was a ~30% 
increase in depolarization of L. monocytogenes populations compared with E. coli O157:H7 
at 60 minutes of incubation.   
Cell Permeability 
 Potassium leakage.  Cell permeability was monitored by two different methods to 
supplement cytometric data.  The first method was monitoring the potassium ion leakage 
from cell cultures treated with colicin E1.  Control cultures of both E. coli O157:H7 and L. 
monocytogenes remained at zero for the length of the experiment.  Treatment with colicin E1 
at 0.1µg/mL on both strains is shown in Figure 4a.  Both strains exhibited similar potassium 
leakage patterns over the 40 minute period.  At 40 minutes, it appeared that L. 
monocytogenes had loss slightly more potassium compared to E. coli O157:H7.  Figure 4b 
represents treatment of cultures with colicin E1 at 1.0µg/mL.  Treatment with a 10-fold 
higher amount of colicin E1 had very comparable results to the 0.1µg/mL dose, with the 
exception that the rate of potassium loss was higher with the higher dose (Figure 4b).   
 Protein leakage.  The second method of cellular permeability analysis was 
spectrophotometric measurement of protein leakage (260nm).  Figure 5a-c shows the changes 
in protein leakage of treated and untreated bacterial cultures at 5(a), 60(b), and 120(c) 
minutes incubation with 0.1, 10, and 100µg/mL colicin E1.  These figures show clear cellular 
damage due to treatment with colicin E1 at all concentrations.  Only slight differences were 
observed between L. monocytogenes and E. coli O157:H7 cultures at 60 minutes of 
incubation.  Data indicate similar leakage rates and volumes for each treated cell culture over 
the course of the experiment.  
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Microscopic Visualization 
 Transmission electron microscopy.  Figure 7a portrays untreated L. monocytogenes 
cells that were subsequently detected using the colicin-E1 antibody and the gold-conjugated 
secondary antibody.  There was virtually no nonspecific binding to these cells.  Figure 6b-d 
were taken at various incubation times at a colicin E1 dose of 1.0µg/mL.  Colicin E1 
appeared to migrate from the peptidoglycan layer into the cytoplasm as the time in incubation 
advanced.  Untreated L. monocytogenes control cells remained viable and intact at 60 
minutes of incubation (Figure 6a).  After 10 minutes of incubation with 1.0µg colicin E1/mL, 
cells appear intact with a high concentration of colicin E1 localizing throughout the 
membrane and into the cytoplasm of L. monocytogenes (Figure 6b).  After 30 minutes of 
incubation, some cells in the culture appeared to have lost complete membrane integrity, 
whereas others were similar to those seen at 10 minutes of incubation.  In the intact cell, 
colicin E1 appears to have fully migrated into the cytoplasm and off of the membranous 
region.  At 60 minutes, there was complete cellular loss of integrity and death (Figure 6d).  
Debris surrounding the dying cell was heavily coated with colicin E1.   
Target Detection   
 A cell lysate containing biotinylated colicin E1 and L. monocytogenes (4 log10 
CFU/mL) was incubated and eluted using an Immunopure™ immobilized monomeric avidin 
column.  Column wash fractions were collected prior to protein elution, run on an 8%  
SDS-PAGE mini-gel, and silver stained for protein detection.  Stained gels from the collected 
wash fractions (columns 2–7) held virtually no detectable protein (Figure 7a).  Elution 
fractions were similarly collected and analyzed, as shown in Figure 7b.  Four clear bands 
were detected in lanes 2–5 of the gel, decreasing in intensity as fraction number increased 
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from the first elution.  Band #1 had an approximate molecular weight of  ~100-130 kDa.  
Band #2 was slightly lower on the gel and had an approximate molecular weight of 90 kDa.  
Band #3 was presumably the loaded colicin E1, as the approximate molecular weight was 
~50-60 kDa.  Colicin E1 has a molecular weight of 56 kDA.  Band #4 had the lowest 
intensity of all of the bands and had an approximate molecular weight of ~10-15 kDA.  
 Protein identification.  Proteins identified from MALDI-TOF digestion are presented 
in Table 1.  Digested protein masses were compared with the NCBInr microbiological 
database.  For each band, five proteins with highest molecular weight score (MOWSE) and 
sequence homology were reported.  The protein from that group with the highest homology 
to the experimental protein data was chosen.  Band #1 had over 80% homology with the 
experiment protein and was identified as DNA Polymerase III of L. monocytogenes.  DNA 
polymerase III is involved in bacterial protein synthesis.  The second band was identified as 
LepA, a GTP-binding protein in the cytoplasmic membrane of L. monocytogenes.  LepA 
belongs to the GTPase family of proteins and is involved in protein translation.  The third 
protein band (MW ~50-60 kDa) was identified as colicin E1 from E. coli.  The final protein 
band was identified as Cell wall surface anchor family protein of L. monocytogenes.  This 
protein had the lowest homology with only 71% homology to the experimental data.   
Discussion 
 Colicins are plasmid-produced antibacterial peptides produce by Escherichia coli 
species.  All colicins exhibit the same structural organization in which three domains 
orchestrate the functions of each colicin.  The central regions of each molecule make up the 
receptor binding domain that forms unique structures that bind to outer membrane receptor 
proteins (8).  The amino-terminus acts in “unknown” ways during the transport of the toxin 
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through the outer membrane of gram-negative bacteria (1, 4) and has been shown to interact 
with either the Tol protein system (group A colicins) or the TonB system (group B colicins).  
The third domain is the “cytotoxic” domain and functions regardless of which colicin group 
it belongs to.  For instance, colicin E3 is a group A colicin that functions as a cytotoxic 
ribonuclease that specifically cleaves 16S rRNA at the ribosomal A-site to abolish protein 
synthesis in sensitive Escherichia coli cells (26).  Colicin E1, the colicin used in these 
experiments, is also a group A colicin but functions as a pore-former.  The one characteristic 
that all colicins are noted for is the narrow range of activity against target bacteria.  The 
reason behind this has been hypothesized that colicins are cytotoxic only against E. coli and 
closely related bacteria because more distantly related bacteria lack a suitable receptor and/or 
translocation system for uptake of the colicin (5).  
 Colicin E1 is clearly effective against both gram-negative and gram-positive species.  
When treated with a membrane-potential sensitive probe (DiBAC(4), L. monocytogenes cells 
were rapidly depolarized by colicin E1.  L. monocytogenes cells were 30% more depolarized 
at 60 minutes of incubation compared to E. coli O157:H7 cultures treated with the same 
colicin E1 concentration (Figures 2 and 3).  Supplementing the flow cytometry data are the 
two permeability assays conducted on both cultures.  Potassium and protein leakage from 
each culture was similar at each time point and with each colicin E1 concentration.  One 
reason the further extent of depolarization was not detected in the permeability assays was 
the detection level of the assay.  Flow cytometric analysis has a much lower detection 
capacity compared to spectrophotmetric methods.  Also, over 10,000 events were recorded 
on the cytometer for each bacterial sample.  The spectrophotometric assays were done in 
triplicate.  
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 In order to visualize membrane depolarization, transmission electron microscopy 
(TEM) was used.  The immunocytochemical techniques enabled viewing of colicin E1 
directly acting on L. monocytogenes cells (Figure 6).  Images showed a clear movement of 
colicin E1 from the peptidoglycan region of the cell inward to the cytoplasm as time 
progressed.  After 30 minutes in incubation with colicin E1, L. monocytogenes cellular 
cytoplasm was completely filled with colicin, and cells began to lyse.  If colicin E1 were 
truly creating pores in the membrane of L. monocytogenes, it is unclear why colicin 
concentrations move into the cytoplasm.  In Figures 8a-b, there are clearly defined pore-like 
openings in the membrane that are labeled with colicin E1.  Although pore-formation did 
occur in these particular cells, this observation was not noted on the majority of treated cells.  
No similar colicin microscopy work has been documented; however, similar electron images 
were observed when Listeria innocua cultures were treated with the gram-positive 
bacteriocin nisin (2).  In that study, cells inhibited cytoplasmic clumping, leakage of cellular 
material, and rupture of the cell walls and cell membranes.  Nisin efficiently inactivates 
bacteria through a unique mechanism which includes inhibition of cell wall biosynthesis and 
pore formation in cytoplasmic membranes.  Both mechanisms are based on interaction with 
the cell wall precursor lipid II which is simultaneously used as target and pore constituent 
(11).  Colicin E1 may be acting on lipid II in L. monocytogenes cells in a similar manner.  
Hyde et al. (12) provided electron micrograph images of the gram-positive bacteria Bacillus 
subtilus with or without treatment with nisin at 5µg/mL.  In that study, cells treated with 
nisin had clearly visible zones of cell wall separation from the cytoplasmic membrane.  In the 
current experiment, cell wall separation was not observed in any of the electron images.  If 
colicin is acting on lipid II (similar to nisin), this molecule presumably would have been 
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detected during the protein target and identification assays utilized in these experiments.  
Elution fractions holding tightly bound colicin E1-protein complexes were analyzed by 
trypsin digestion using MALDI-TOF and were identified as DNA polymerase III, the  
GTP-binding protein LepA, and Cell wall surface anchor family protein, all of L. 
monocytogenes (Table 1).  The fourth band was identified to be colicin E1 based on 
molecular weight and similarity to loaded colicin E1 on silver-stained SDS-PAGE mini-gels 
(Figures 8a-b).   
 DNA polymerase III is the primary enzyme of DNA replication, which functions by 
adding deoxynucleotides corresponding to the newly synthesized DNA strand.  LepA is also 
associated with protein synthesis and has recently been described as the third elongation 
factor required for accurate and efficient protein synthesis in bacteria.  LepA has the unique 
function of back-translocating post-translocational ribosomes.  Due to this characteristic, the 
function of LepA is to recognize and fix translocation errors (16, 29).  DNA polymerase III is 
a cytoplasmic protein, whereas LepA is situated on the cytoplasmic membrane.   
 Colicin E1, up to this point, was thought primarily to interact with surface lipids and 
proteins in a toroidal organization forming a channel pore (22, 27).  There has been no 
literature explaining any interaction of the pore-forming colicin E1 with DNA, RNA, or 
tRNA related enzymes.  The majority of enzymatic colicins that have been described target 
phosphodiester bonds in the bacterial cytoplasm, eliciting cell death as either hydrolases or 
transferases.  This varied group of enzymes target genomic DNA (DNases), 16S rRNA 
(rRNases), or tRNAs (tRNases).  Only two nuclease colicins, E5 and D, do not hydrolyze 
phosphodiester bonds, but rather act as phosphotransferases (5).  These data indicate that 
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colicin E1 interacts with several proteins in L. monocytogenes that are not directly associated 
with the mechanism of any other colicin.   
 The last protein identified, Cell wall anchor family protein, is involved in cell wall 
stabilization and attachment to the cytoplasmic membrane (13).  Although this protein has 
not been previously identified in colicin E1 mechanism research, it seems logical that a  
pore-forming protein would interact with a surface protein of this nature.  Given these 
intriguing experimental outcomes, a possibility to the mechanism of colicin would be that it 
accumulates in the cytoplasm of the cell through passive diffusion over the peptidoglycan 
layer.  Once situated along the inner membrane, the cytotoxic domain of colicin E1 may form 
an intermediate pore.  This formation would explain the interaction with cell wall anchor 
family protein, as well as LepA, whom are associated with the cell membrane.  It is 
premature to fully explain the mechanism of colicin E1 on L. monocytogenes at this point; 
however, the protein identification of DNA polymerase III, as well as LepA, provide 
intriguing insight to a novel mechanism taken by colicin E1 against gram-positive bacteria.   
Conclusions 
 This research indicates a novel mechanism incorporated by colicin E1 against the 
gram-positive pathogen Listeria monocytogenes.  While similar membrane depolarization 
was observed between L. monocytogenes and E. coli O157:H7 treated with colicin E1, 
immunocytochemical images followed the rapid movement of colicin E1 from the 
cytoplasmic membrane into the cytoplasm.  Structural damage to L. monocytogenes cells was 
similar to what has been observed with the bacterioicn nisin against gram-positive bacteria, 
indicating a possible connection between colicin E1 and the cytotoxic mechanisms employed 
by nisin.  Bacterial proteins having affinity to colicin E1 were identified as DNA polymerase 
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III, LepA, and a cell wall anchor family protein by use of monomeric avidin affinity 
chromatography and MADLI-TOF.  Colicin E1 is the first colicin to have reported affinities 
with these proteins, which is a pivotal step in understanding the mode-of-action this 
bacteriocin implements against gram-positive bacteria.   
Acknowledgements 
 This work could have not been accomplished without the expertise of Tracey Pepper, 
M.S., of the Iowa State University Microscopy and Nano-Imaging Facility, as well as Shawn 
Rigby, PhD., of the Iowa State University Flow Cytometry and Cell Hybridoma Facility.  
This research was funded in part by the Biotechnology Research and Development 
Corporation (BRDC), the Tri-State Food Safety Consortium, and the ISU Institute for Food 
Safety and Security.  
References   
1.  Bouveret, E., A. Rigal, C. Lazdunski, and H. Benedetti. 1998. Distinct regions of the 
colicin A translocation domain are involved in the interaction with TolA and TolB proteins 
upon import into Escherichia coli. Mol. Microbiol. 27:143–157. 
2.  Calderón-Miranda, M. L., G. V. Barbosa-Cánovas, and B. G. Swanson. 1999. 
Inactivation of Listeria innocua in skim milk by pulsed electric fields and nisin. Int J Food 
Microbiol. 51:19–30.  
3.  Cao, Z., and P. E. Klebba. 2002. Mechanisms of colicin binding and transport through 
outer membrane porins. Biochimie. 84:399–412.  
 
 
 120  
 
4.  Carr, S., C. N. Penfold, V. Bamford, R. James, A. M. Hemmings, J. K. Davies, and P. 
Reeves. 2000. The structure of TolB, an essential component of the tol-dependent 
translocation system, and its protein–protein interaction with the translocation domain of 
colicin E9. Structure. 8:57–66. 
5.  Cascales, E., S. K. Buchanan, D. Duché, C. Kleanthous, R. Lloubès, K. Postle, M. 
Riley, S. Slatin, and D. Cavard. 2007. Colicin biology. Microbiol. Mol. Biol. Rev.  
71:158–229.  
6.  Cleveland, J., T. J. Montville, I. F. Nes, and M. L. Chikindas. 2001. Bacteriocins: safe, 
natural antimicrobials for food preservation. Int. J. Food Microbiol. 71:1–20.  
7.  Cotter, P. D., C. Hill, and R. P. Ross. 2005.  Bacteriocins: developing innate immunity 
for food. Nat. Rev. Microbiol. 3:777–788.  
8.  Di Masi, D. R., J. C. White, C. A. Schnaitm, and C. Bradbeer. 1973. Transport of 
vitamin B12 in Escherichi coli: common receptor sites for vitamin B12 and E. colicins on 
outer membrane of cell envelope. J. Bacteriol. 115:506–513.  
9.  Ennahar, S., K. Sonomoto, and A. Ishizaki. 1999. Class IIa bacteriocins from lactic acid 
bacteria: antibacterial activity and food preservation. J. Biosci. Bioeng. 87:705–716.  
10.  Gould, J. M. and W. A. Cramer. 1977. Studies on depolarization of Escherichia coli 
cell-membrane by colicin E1. J. Biol. Chem. 252:5491–5497.  
11.  Hasper, H. E., N. E. Kramer, J. L. Smith, J. D. Hillman, C. Zachariah, O. P. 
Kuipers, B. de Kruijff, and E. Breukink. 2006. An alternative bactericidal mechanism of 
action for lantibiotic peptides that target lipid II. Science. 313:1636–1637.  
 121  
 
12.  Hyde, A. J., J. Parisot, A. McNichol, and B. B. Bonev. 2006. Nisin-induced changes in 
Bacillus morphology suggest a paradigm of antibiotic action. Proc. Natl. Acad. Sci. 
103:19896–19901.  
13.  Nelson, K. E., D. E. Fouts, E. F. Monogodin, J. Ravel, R. T. DeBoy, J. F. Kolonay, 
D. A. Rasko, S. V. Angiuoli, S. R. Gill, I. T. Paulsen, J. Peterson, O. White, W. C. 
Nelson, W. Nierman, M. J. Beanan, L. M. Brinkac, S. Daugherty, R. J. Dodson, A. S. 
Durkin, R. Madupu, D. H. Haft, J. Selengut, S. Van Aken, H. Khouri, N. Federova, H. 
Forberger, B. Tran, S. Kathariou, L. D. Wonderling, G. A. Uhlich, D. O. Boyles, J. B. 
Luchansky, and C. M. Fraser. 2004. Whole genome comparisons of serotype 4b and 1/2a 
strains of the food-borne pathogen Listeria monocytogenes reveal new insights into the core 
genome components of this species. Nucleic Acids Res. 32:2386–2395.  
14.  Orlov, D. S., T. Nguyen, and R. I. Lehrer. 2002. Potassium release, a useful tool for 
studying antimicrobial peptides. J. Microbiol. Methods. 49:325–328.  
15.  Patton, B. S., J. S. Dickson, S. M. Lonergan, S. A.Cutler, and C. H. Stahl. 2007. 
Inhibitory activity of colicin E1 against Listeria monocytogenes. J Food Prot. 70:1256–1262. 
16.  Qin, Y.,  N. Polacek, O. Vesper, E. Staub, E. Einfeldt, D. N. Wilson, and K. H. 
Nierhaus. 2006. The highly conserved LepA is a ribosomal elongation factor that  
back-translocates the ribosome. Cell. 127:721–733.  
17.  Riley, M. A., and D. M. Gordon. 1996. The ecology and evolution of bacteriocins. J. 
Ind. Microbiol. 17:151–158.   
18.  Schamberger, G. P., R. L. Phillips, J. L. Jacobs, and F. Diez-Gonzalez. 2004. 
Reduction of Escherichia coli O157:H7 populations in cattle by addition of colicin  
E7-producing E. coli to feed. Appl. Environ. Microbiol. 70:6053–6060.  
 122  
 
19.  Schendel, S. L., E. M. Click, R. E. Webster, and W. A. Cramer. 1997. The TolA 
protein interacts with colicin E1 differently than with other group A colicins. J. Bacteriol. 
179:3683–3690.  
20.  Shin, Y. K., C. Levinthal, F. Levinthal, and W. L. Hubbell. 1993. Colicin E1 binding 
to membranes—Time resolved studies of spin-labeled mutants. Science. 259:960–963.  
21.  Smarda, J., and L. Macholan. 2000. Binding domains of colicins E1, E2 and E3 in the 
receptor protein BtuB of Escherichia coli. Folia Microbiol. 45:379–385.  
22.  Sobko, A. A., E. A. Kotova, Y. N. Antonenko, S. D. Zakharov, and W. A. Cramer. 
2006. Lipid dependence of the channel properties of a colicin E1-lipid toroidal pore. J Biol 
Chem. 281:14408–14416. 
23.  Stahl, C. H., T. R. Callaway, L. M. Lincoln, S. M. Lonergan, and K. J.Genovese. 
2004. Inhibitory activities of colicins against Escherichia coli strains responsible for 
postweaning diarrhea and edema disease in swine. Antimicrob Agents Chemother.  
48:3119–3121.  
24.  Tilley, S. J, and H. R. Saibil. 2006. The mechanism of pore formation by bacterial 
toxins. Curr. Opin. Struct. Biol. 16:230–236.  
25.  Trautner, B. W., R. A. Hull, and R. O. Darouiche. 2005. Colicins prevent 
colonization of urinary catheters. J. Antimicrob. Chemother. 56:413–415.  
26.  Walker, D., L. Lancaster, R. James, and C. Kleanthous. 2004. Identification of the 
catalytic motif of the microbial ribosome inactivating cytotoxin colicin E3. Protein Sci. 
13:1603–1611.  
 123  
 
27.  White, D., A. A. Musse, J. Wange, E. London, and A. R. Merrill. 2006. Toward 
elucidating the membrane topology of helix two of the colicin E1 channel domain. J. Biol. 
Chem. 281:32375–32384.  
28.  Wickens, H. J., R. J. Pinney, D. J. Mason, and V. A. Gant. 2000. Flow cytometric 
investigation of filamentation, membrane patency, and membrane potential in Escherichia 
coli following ciprofloxacin exposure. Antimicrob. Agents Chemother. 2000. 44:682–687.   
29.  Youngman, E. M, and R. Green. 2007. Ribosomal translocation: LepA does it 
backwards. Curr. Biol. 17:R136–R139.  
Figure Legends 
Figure 1.  Biotinylation of colicin E1.  Colicin E1 concentrations were tested for  
  successful  biotinylation by western dot-blotting (1A).  Colicin E1   
  concentrations of 5, 10, and 20µg/mL were added on left hand side on   
  PVDF membrane.  Biotinylated colicin E1 concentrations of equal   
  concentrations were added on the right-and side.  For reference, a 1:2000  
  dilution of biotin was placed in-between both sides on a drawn-line. Dots  
  from the biotnylated colicin E1 were clearly detected using ECL plus™.   
  Figure 1B shows growth and inhibition of L. monocytogenes over a 6 hour period. 
  ■ = 0, Control; 0; ● = 1µg/mL colicin E1; ○ = 1µg/mL biotinylated colicin E1.  
Figure 2.  Colicin E1 activity against Escherichia coli O157:H7.  Flow cytometric  
  analysis of E. coli O157:H7 treated with colicin E1.  Cell integrity   
  histograms show a: untreated E. coli O157:H7 samples at 60 minutes of  
  incubation at 37°C.  b: E. coli O157:H7 samples treated with 1.0µg/mL  
  colicin E1.   
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Figure 3.  Colicin E1 activity against Listeria monocytogenes.  Flow cytometric  
  analysis of L. monocytogenes treated with colicin E1 using the membrane- 
  potential sensitive probe DiBAC(4). a: Untreated L. monocytogenes at 30  
  minutes of incubation at 37°C. b: L. monocytogenes samples treated with  
  0.1µg/mL colicin E1, 30min. c: L. monocytogenes samples treated with  
  1.0µg/mL colicin E1, 30min. d: Untreated L. monocytogenes at 60   
  minutes of incubation at 37°C. e: L. monocytogenes samples treated with  
  0.1µg/mL colicin E1, 60min. f: L. monocytogenes samples treated with  
  1.0µg/mL colicin E1, 60min. Percentage of depolarized sample population  
  is indicated above histogram (%).  
Figure 4.  Potassium leakage induced by colicin E1.  L. monocytogenes and E. coli  
  O157:H7 cultures were treated with 0 (control) 0.1 (a) or 1.0µg/mL (b)  
  colicin E1, and potassium leakage was measured using a pH-meter pH 213  
  with a MI-442 potassium electrode and MI-409F reference electrode. 
    Calculations of potassium-efflux in percent as % release = ([K+]meas –   
  [K+]init / [K+]total) – [K+]init x 100. ■ = L. monocytogenes (FSIS 1126); □ 
   = E. coli O157:H7 strain 933; X = Untreated L. monocytogenes (FSIS   
  1126); ∆ = Untreated E. coli O157:H7.   
Figure 5.  Protein leakage induced by colicin E1.  L. monocytogenes and E. coli   
  O157:H7 were treated with either 0, 0.1 or 1.0µg/mL of colicin E1, and  
  protein leakage was measured spectrophotometrically at 260nm at various  
  time points up to 120 minutes of incubation at 37°C.  5a represents protein  
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  leakage at five minutes of incubation, 5b at 60 minutes, and 5c at 120   
  minutes.  ■ = L. monocytogenes (FSIS 1126); □ = E. coli O157:H7 strain  
  933; ∆ =  Untreated L. monocytogenes (FSIS 1126).  
Figure 6.  Colicin E1-treated L. monocytogenes cells over 60-min period.    
  Transmission electron microscopic images validate the effects of colicin  
  E1 against the gram-positive pathogen. Untreated L. monocytogenes cells  
  appear healthy at 60 minutes of incubation at 37°C.  Cells treated with   
  1.0µg/mL of colicin E1 are shown at 10  minutes (b), 30 minutes (c) and  
  60 minutes (d) of incubation.   
Figure 7.  L. monocytogenes proteins with affinity to colicin E1.  Biotinylated   
  colicin E1  was combined with L. monocytogenes cultures (4 log10   
  CFU/mL), incubated, and eluted using an Immunpure™ immobilized   
  monomeric avidin column. Column wash fractions (8a) were loaded on an  
  8% SDS-PAGE mini-gel (lanes 2-7), as well as a load sample of   
  biotinylated colicin E1 (lane 1) and a molecular weight  standard (8), and  
  detected using silver staining.  Column elution fractions (8b) were loaded  
  and ran in similar manner (lanes 2-8) with a molecular weight standard  
  (lane 1).  Four visible protein bands were detected as indicated by arrows.   
Figure 8.  Pore-formation by colicin E1 in Listeria monocytogenes.  Cell walls of  
  L. monocytogenes with large openings enveloped with gold-labeled colicin  
  E1.  Arrows indicate areas of pore-formation.   
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Table 1.  Identification of elution fraction protein fragments associated with 
               colicin E1. 
Band 
Number Identification Species MOWSEa PCb SC%c 
Accession 
Numberd 
1 
DNA 
Polymerase III, 
alpha subunit 
Listeria 
monocytogenes 171 20/24 34 
AAT 
04371 
2 LepA, GTP-binding protein 
Listeria 
monocytogenes 115 15/20 29 CAC99557 
3 Colicin E1 Escherichia 
coli 98 22/23 18 AAY68489 
4 
Cell wall 
surface anchor 
family protein 
Listeria 
monocytogenes 113 12/17 32 AAT04978 
a
  MOWSE score: statistical probability of true positive identification of predicted proteins calculated by 
MS-fit with 50 ppm masses tolerance and one allowed missed cleavage (MOWSE score ≥ 66). 
b
  PC: number of peptides matching predicted protein sequences. 
c
  SC%: percentage of predicted protein sequence covered by matched sequences. 
d
  Accession no.: the identification of predicted protein in NCBInr. 
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Figure 1.  Biotinylation of colicin E1. 
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Figure 2. Colicin E1 activity against Escherichia coli O157:H7.   
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Figure 3.  Colicin E1 activity against Listeria monocytogenes. 
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Figure 4.  Potassium leakage induced by colicin E1. 
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Figure 5.  Protein leakage induced by colicin E1.  
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     Figure 6.  Colicin E1-treated L. monocytogenes cells over 60-min period. 
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Figure 7.  L. monocytogenes proteins with affinity to colicin E1. 
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       Figure 8.  Pore-formation by colicin E1 in Listeria monocytogenes. 
 135 
 
CHAPTER 5.  GENERAL CONCLUSIONS 
General Discussion 
 Antimicrobial intervention strategies are rapidly being optimized to replace previous 
antibiotic strategies.  Concerns surrounding antibiotic resistance and overall bacterial fitness 
strategies are driving these efforts towards natural, non-synthetic compounds with little to no 
toxicity towards animals and humans.  Controlling bacterial contamination in livestock 
production and transport, animal slaughter and meat processing facilities, as well as dips, 
sanitizers, and food packaging systems is imperative in preventing catastrophic outbreaks of 
pathogenic microorganisms.  An intervention strategy, as noted in this dissertation, is the  
use of the bacteriocins colicin E1, produced by Escherichia coli.  In a 98% pure form, 
concentrations as low as 0.1µg/mL of colicin E1 was able to inhibit growth of L. 
monocytogenes for a duration of 6 hours at 37°C.  Colicin E1 appears to be more effective 
against the gram-positive L. monocytogenes compared to E. coli, which was observed using 
flow cytometry, potassium and nucleic acid leakage assays, as well as broth culture inhibition 
studies.  Colicin E1 appears to be acting upon these gram-positive pathogens in a novel 
mechanism compared to the well orchestrated and documented pore-formation against E. coli 
(1, 2).  Recovered proteins with high affinity to colicin E1 using an immobilized monomeric 
avidin column and biotinylated colicin E1 included DNA polymerase III, LepA, Cell wall 
anchor family protein of L. monocytogenes.  No other colicin has been reported to interact 
with these proteins, suggesting that colicin E1 is acting atypically on L. monocytogenes.  
While pore-formation did occur in treated few L. monocytogenes cells, colicin E1 appeared 
to localized in the cytoplasm of infected cells until lysis.  It is obvious that this bacteriocins  
 136 
 
is effective at inhibiting pathogenic bacteria, however, the mechanism by which this 
bacteriocins is causing the fate of gram-positive bacteria remains unknown.  
Recommendations for Future Research 
 We have successfully biotinylated the colicin E1 molecule without impacting its 
antimicrobial activity.  Also, a polyclonal antibody was produced in rabbits that showed little 
to no non-specific binding when used in various immunological assays.  Using this antibody 
could be used in certain activity assays of colicin E1 on purified DNA polymerase III-mutant 
bacteria.  Staining and localization methods of these proteins within bacterial cells to 
negotiate binding within cell culture to colicin E1 would also be beneficial. Also, if direct 
activity against these enzymes was noted, colicin-E1 could be prepared and purified to  
over-express factors capable of recognizing these enzymes, making the colicins more highly 
active against L. monocytogenes.  Lastly, immunoprecipitation with membrane proteins of L. 
monocytogenes might give an insight into other protein systems or localization of the 
interaction that colicin E1 has with these proteins in terms of cellular constituents, including 
the cell membrane and peptidoglycan later.  Other possible experiments could be to test 
nuclease activity on L. monocytogenes RNA or DNA-containing agar.  This would allow us 
to evaluate if colicin E1 did indeed have nuclease activity against L. monocytogenes at all.  
Also, truncating the colicin E1 molecule to the c-terminus, and determining the location of 
import along the inner membrane.  
 In more applied terms, to evaluate the efficacy and possibility of this bacteriocin to be 
used as a food bio-preservative, a more thorough characterization of shelf-life extension 
made possible by colicin E1 treatment needs to be conducted. An accurate dose-response 
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relationship and subsequent impact on surviving cells would be an important step in 
determining the amount required to provide static or toxic control in an industrial setting.   
Lastly, L. monocytogenes is the only gram-positive organism known to contain trace 
quantities of LPS.  It may be beneficial to denote affinity of colicin E1 to L. monocytogenes 
LPS.   
 In conclusion, we have only begun to understand colicins themselves; their actions 
against their common host, Escherichia coli, and how differing colicins employ opposing 
strategies upon reaching and infiltrating a target cell.  Now, we are faced with further 
knowledge that these bacteriocins indeed have a broader spectrum of activity than originally 
anticipated, and interestingly, a novel mode-of-action to initiate this activity.  Given this first 
chapter of exploratory research, much more work needs to conducted to examine the 
possibilities of colicins, both in nature, and applied uses to benefit people and animals.  
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